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Two different radiation detection instruments, both commonly found in nuclear 
medicine clinics, were investigated for potential use in 125I brachytherapy seed source 
strength verification.  The goal of this investigation was to determine if either or both of 
these instruments could replace the air-communicating well-type ionization chamber 
(standard source strength verification instrument) when the 125I seed is used for 
radioactive seed localization procedures instead of brachytherapy.   In radioactive seed 
localization, the 125I seed merely localizes the tissue of interest and does not deliver a 
therapeutic dose to the patient.  The 125I seeds are inserted into nonpalpable lesions, 
which are then removed for biopsy within 5 days.  Dose calculations and patient 
modeling are not performed.  As a result of this, stringent source strength accuracy 
tolerances are not necessary.  The accuracy, precision, and reproducibility of an activity 
 iv 
calibrator and an ionization chamber survey meter were assessed and compared to 
regulatory requirements.   
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The use of sealed source radioactive material for brachytherapy cancer treatments 
originated over 100 ago years with the pioneering 226Ra research by Pierre and Marie 
Curie (Schwartz et al. 2012).  125Iodine (125I) was first used for interstitial brachytherapy 
in 1965, and its use has increased over time in both volume and variety of applications.  
The first American Association of Physicists in Medicine (AAPM) report formalizing 
relevant brachytherapy quality assurance (QA) procedures and safety guidelines was 
published in 1984 (Svensson 1984).  The procedures have evolved in the various AAPM 
reports since then, and thus far, all of the rules and procedures recommended have been 
specific to therapeutic use of these sources.  In the late 1990s, a novel use of 125I 
brachytherapy seeds for the localization of non-palpable breast abnormalities in a 
procedure called radioactive seed localization (RSL) was first reported (Dauway et al. 
1999).     
The intent of the RSL procedure is not therapeutic, and thus the demands of the 
physicist are not necessarily the same as for brachytherapy.  Most importantly, the dose 
to the patient is much smaller, and there is no detailed dosimetry calculation and 
treatment planning.  The primary concerns for the physicist are keeping the patient dose 
as low as reasonably achievable (ALARA) while still maintaining seed activity that is 
sufficient for the surgeon to be able to find it with a gamma probe.  Currently, there are 
no published recommended procedures for how to verify the vendor source strength 
calibration of the RSL seeds.  Physicists have been left to determine if seeds should be 
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calibrated according to brachytherapy recommended procedures or nuclear medicine 
(normally unsealed radioactive material) methods and tolerances.  At MD Anderson 
Cancer Center (MDACC) we adopted 125I seed source strength verification procedures 
similar to that of brachytherapy.  This required the purchase of instrumentation not 
commonly owned or used by nuclear medicine departments.  It would be far easier for 
clinics starting a new RSL program to use instruments that their staff is already familiar 
with.  This is the approach that the Mayo Clinic in Scottsdale, Arizona took (Pavlicek et 
al. 2006).  Both IsoAid (RSL seed vendor) and the National Physical Laboratory (the 
United Kingdom’s National Measurement Institute) also use pressurized well chambers 
to calibrate brachytherapy seeds (Baker et al. 2002; IsoAid 2014).  The objective of this 
thesis is to investigate the use of two common nuclear medicine instruments, the activity 
calibrator (commonly referred to as dose calibrator or radionuclide calibrator) and the 
ionization chamber survey meter, for the purpose of source strength verification.  A batch 
set of 125I calibration seeds were calibrated on the system currently in place (air-
communicating ionization well chamber, designed for measurement of brachytherapy 
seeds) and then used to determine the correct calibration setting for the activity calibrator 
and calibration factor for the ionization chamber survey meter.  The instruments will be 







Brachytherapy is a cancer treatment whereby a radioactive source is inserted into 
or next to cancerous tissue.  “Brachy” means “short distances”, hence the name 
brachytherapy (IAEA 2005).  In many situations where brachytherapy is an applicable 
treatment modality, traditional external radiation beam therapy could also be used.  
Brachytherapy has the advantage of a more controlled dose distribution.  Since the 
radioactive source is implanted near, or within, the tumor, it is this tumor that receives the 
largest dose (Schwarz et al. 2012).  With an appropriately selected radionuclide and 
initial radioactivity, dose to healthy tissue can be minimized.  This is contrary to external 
beam therapy where there can be significant dose to the healthy tissue surrounding the 
tumor due to the x-ray beam path passing through the healthy tissue before and after 
interacting with the tumor (entrance and exit dose).  Some cancers typically treated with 
brachytherapy include prostate, cervical, breast, lung, esophageal, eye, and head and 
neck.  Brachytherapy is often used in combination with external beam therapy (Khan 
1984).       
Brachytherapy specifically refers to sealed radioactive sources.  Therefore, in 
brachytherapy, the treatment location can be controlled with great precision.    Dose rates 
can vary from 0.4 to 2 Gy hr-1 in Low Dose Rate (LDR) brachytherapy to over 12 Gy hr-1 
in High Dose Rate (HDR) brachytherapy (ICRU 1985).  The brachytherapy source 
placement can be either temporary or permanent.  Temporary placements range from 
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minutes to hours.  Permanent implants require radionuclides that decay over a few 
months’ time, after which the source remains in place.  The radionuclides typically used 
for brachytherapy include 137Cs, 60Co, 192Ir, 90Sr/90Y and 106Ru for temporary placement 
and 125I and 103Pd for permanent placement (IAEA 2005). 
125Iodine brachytherapy seeds are small and cylindrical with dimensions of 4.5 to 
5 mm in length and less than 1 mm in diameter (Rivard 2004).  The external shell is 
titanium, and the interior consists of either tiny resin spheres or silver wires with the 
radionuclide absorbed onto them (Kutchur et al. 1994).  125Iodine decays by electron 
capture to an excited state of tellurium-125 (125Te), which immediately stabilizes by 
emitting a 35.5 keV gamma-ray (Nath et al. 1995).  Characteristic x-rays between 27-32 
keV as well as Auger electrons are also emitted during the 125I electron capture process.  
At these energies, penetrability is limited (2 mm half-value layer in tissue), and the 
energy is deposited in a highly localized manner, which reduces dose to healthy tissue 
surrounding the cancer cells (Barnett et al.  2007; Schwarz et al. 2012).  Due to this low-
energy radiation and a relatively short half-life of 59.4 days, 125I is considered an optimal 
permanent implant brachytherapy source.   
125Iodine brachytherapy is commonly used to treat prostate cancer, brain cancer, 
and cancers of the eye.  For brachytherapy to be effective, the cancer must be treated at 
an earlier stage before it has spread significantly to other organs, as it is not effective 
against tumors that are larger and not well localized (IAEA 2005).  The brachytherapy 
treatment process begins with tumor volume characterization through clinical 
examination with the assistance of radiography, computed tomography (CT), positron 
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emission tomography (PET), ultrasound and magnetic resonance imaging (MRI) (ICRU 
1993, ICRU 1997).   Once an appropriate model of the tumor volume and surrounding 
tissue has been generated, radioactive source strength and placement must be determined 
in order to assure sufficient distribution of dose throughout the treatment area while 
minimizing dose to healthy tissues.  For this process to be successful, the radiation field 
emitted from the brachytherapy source must be very well characterized so that the 
administered dose follows the treatment planning accurately (Schwarz et al. 2012).  
AAPM Report No. 51 specifies interstitial brachytherapy seed dosimetry 
calculation methods including relevant parameters and acceptable levels of uncertainty 
(Rivard et al. 2004).  The general formalism assumes a cylindrical seed and yields the 
dose rate, D(r,θ), at a point external to the source with position given in polar coordinates.  
The estimated total 1σ uncertainty in D(r,θ) is about 6.7%, 5.7%, and 7.3% at 0.1, 1, and 
5 cm, respectively.  The other quantities that make up the general formalism include the 
air kerma strength, Sk in units of cGy cm2 h-1, the dose rate constant, ^ in units of cm-2, 
the geometry function, G(r,θ), the anisotropy function F(r,θ), and the radial dose function 
g(r).  Of these parameters, the clinical medical physicist only measures the air kerma 
strength, with a typical total 2σ uncertainty of about 3%.  The other quantities and their 
associated uncertainties are determined from tabulated data (ICWG 1990, Williamson 
1991, Nath et al. 1995, Rivard et al. 2004).  Air kerma strength is provided by the vendor 
and must be verified by the medical physicist.  The general formulism in polar 
coordinates for the two-dimensional dose rate at a point (r,θ) due to a cylindrical source is 
shown in equation 1.  The angle, θ, refers to the angle relative to the longitudinal axis of 
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the seed.  Note that the formalism assumes that the dose distribution is cylindrically 
symmetric about the longitudinal axis of the seed. 
D(r,θ) = Sk ^ [ GL(r,θ) / GL(r0,θ0) ] gL(r) F(r,θ)  (1) 
where G(r0,θ0) is the geometry factor at a reference point (r0,θ0).   
I-125 Radioactive Seed Localization  
One of the preoperative steps for surgical removal of nonpalpable breast tissue 
abnormalities for biopsy is localization of the lesion so that the surgeon can find it during 
the procedure.  The current standard method of marking the lesion is wire localization 
(WL), a procedure in which a fine needle is used to insert a wire (or multiple wires) into 
the abnormality.  The needle is then removed, and a mammogram is performed to verify 
correct wire placement.  During the lesion removal surgery, ultrasound is used to locate 
the wire, and the surgeon removes the wire and surrounding tissue.  A recently developed 
alternative to WL is a procedure called radioactive seed localization (RSL).  In RSL 
small, low-activity (0.2 mCi (7.4 GBq) nominal activity), 125I brachytherapy seeds, pre-
packaged sterile into a sterilized needle, are inserted into the nonpalpable lesion and 
released from the needle, which is then removed from the breast.  During the surgery, a 
hand-held gamma probe indicates the position of the highest count rate (125I energy 
window) on the surface of the breast.  This is the surgeon’s incision point.  Each seed and 
lesion are then located and removed with continued assistance from the gamma probe 
(Jakub et al. 2010). 
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While WL has proven to be effective, there are several problems associated with 
the procedure (Gray et al. 2004).  The optimal incision point for the wire is not 
concurrent with that of the surgery.  Thus, a compromise must be made on the surgeon’s 
incision point.  It is also difficult during surgery to find the precise location of the wire’s 
end point.  This uncertainty in the wire endpoint location increases the risk of either 
removing too much or too little tissue.  The wire may even be cut accidentally during 
surgery, leaving part of the wire in the body and making the lesion more difficult to 
locate.  
All of these problems are reduced or eliminated in RSL procedures.  With RSL, 
there is a lower rate of repeat surgical procedures.  Subjective patient measures have also 
shown to be favorable for RSL.  The procedure is less painful and more convenient for 
the patient (Pavlicek et al. 2006).  WL procedures must be performed on the same day as 
the surgery, which makes scheduling more difficult for hospital staff.  WL is typically 
performed early in the day, and then the patient must wait until later in the day for the 
actual surgery with very little timing flexibility.  On the other hand, RSL insertion is 
usually performed the day before the surgery, as there is nothing protruding from the 
patient’s body, making it is safe for the patient to leave the hospital. The RSL insertion 
can be performed up to 5 days prior to the surgery.  Exposure rates at contact with the 
breast (needle entry point) range from 0.2 to 187 µSv h-1 and 0.1 to 28 µSv h-1 at 1 m 
(Dauer et al. 2013).  The Nuclear Regulatory Commission (NRC) guidelines allow 
release of patients with 125I implants if the total activity is below 9 mCi (333 Gbq), which 
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is much larger than that which would be expected with RSL procedures (U.S. NRC 
1997).  
RSL is not a therapeutic procedure, and patient dose is very small. The maximum 
dose to residual breast tissue has been calculated to be comparable to that of a two-view 
mammogram (20-30 mGy) (Pavlicek 2006).  Because of this, RSL procedures are less 
dependent on the accuracy of seed activity than when 125I seeds are used in therapeutic 
procedures.  The source strength is still verified (in terms of apparent activity instead of 
air kerma strength), but there is no requirement for dose distribution modeling 
(dosimetry). Nonetheless, some physicists currently verify RSL seed vendor calibration 
by following procedures comparable to standard therapeutic brachytherapy protocol.   
Ionization Chamber  
Chambers filled with air or gases are the most commonly employed and earliest 
form of electrical radiation detectors (Leo 1994).  An ionization chamber consists of an 
outer wall, central anode wire and a fill gas, typically argon or other noble gas, which is 
ionized by incident radiation and secondary electrons from incident photon-wall 
interactions to create ion-electron pairs.  The chamber wall structurally contains the gas, 
sometimes under pressurization, and acts as a cathode.  A high voltage is supplied across 
the detector volume creating an electric field between the central anode and the cathode 
(chamber wall), and this electric field causes the electrons and positive ions to travel 
towards the anode and cathode, respectively.  The electrons, once collected at the anode, 
produce an electric current, which is analyzed by the circuit of the detector system.  The 
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voltage level, and in turn the strength of the electric field, chamber volume and 
pressurization determine the ionization characteristics of the chamber (Turner 2009).  At 
lower operating voltages, electron-ion pairs simply recombine, while at high operating 
voltages, a cascade of secondary ionization events results in large charge pulses for each 
individual primary ionization event.   
Each of the ionization chambers investigated herein is operated in the “ionization 
region” with operating voltages around between 50-300 V.  Ionization events in this 
region result in pulses that are very small.  Thus, they are operated in direct current mode, 
and charge accumulation is measured with an electrometer.  In the ionization region, the 
electric field is sufficient to prevent recombination, but there are no secondary ionizations 
or charge multiplication factor.  The charge created is then directly proportional to the 
energy deposited into the chamber during the ionization event.  Due to this attribute, 
chambers operated in the ionization region can be used for counting (scaler) applications, 
gamma-ray and x-ray exposure measurements, Air Kerma measurements, and photon 
energy spectroscopy (when operated in pulse mode) (Knoll 2010).  
Ionization Well Chamber 
The well-type ionization chamber is considered standard instrumentation for 
calibrating brachytherapy seeds for the purpose of verifying vendor seed calibration, 
which is an important step in assuring patient dose accuracy.  This instrument is 
recommended by governing bodies, accreditation agencies, and relevant expert groups 
due to its accuracy and long-term stability (Nath et al. 1997; Knoll 2010).  As the name 
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“well chamber” implies, the source is placed into a shielded chamber (like a small well).  
The internal wall is typically made of a thin aluminum alloy (alternatively graphite or air-
equivalent plastic) (Carey et al. 2012). The detector volume (between internal and 
external shielding walls) surrounds the narrow, cylindrical space where the seed is 
inserted.  Within the well chamber, background radiation is extremely low.  This detector 
design is necessary for accurate low activity seed calibration.  Ionization well chamber 
responses are extremely geometry dependent, and as such, the seed is typically placed in 
a thin plastic holder/dipper that is inserted into the well chamber, thus insuring consistent 

















          
             
                 
              
              
              
              
              
                  
                
                
                
                
                
                
                
                
                
                
              
                  
             
                  
           
           
           
           
           
           
          
 











Ionization Well Chamber (air-communicating) 
Some ionization chamber designs involve a gas (other than air) within the 
chamber.  A high-Z gas (typically a noble gas) is preferred in order to maximize electron 
interactions and minimize chemical reactivity (Bushberg et al. 2002).  In designs known 
as air-communicating well chambers, there is no sealed gas.  Instead, a small opening in 
the chamber wall allows air to flow through the chamber, and it is this air that is ionized.  
The advantages of utilizing the natural air in the room include improved detector 
sensitivity to low energy photons (without pressurization the inner shell wall can be 
thinner which decreases photon attenuation), and there is no risk of response instability 
from pressurized gas leaking over time (IAEA 2002).  A downside of this design is the 
need to check pressure and temperature before seed calibration and correct the readings 
according to the variations in atmospheric conditions.   
The air-communicating well chamber detection system consists of a thermometer, 
a barometer, the well chamber itself, and an electrometer.  The thermometer and 
barometer are used to measure atmosphere conditions in the room during the seed assay.  
When using an air-communicating well chamber, the final results of the assay need to be 
adjusted to account for differences in atmospheric pressure relative to that of the 
Accredited Dosimetry Calibration Laboratory (ADCL) room in which the well chamber 
was calibrated.  The current created in the circuit of the ionization chamber is measured 
by an electrometer, which is a device that indirectly measures current by measuring the 
change in potential difference in a circuit without actually drawing any current from the 
circuit (Knoll 2010).  This is particularly important for measurements of ionizing 
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radiation, which involve charge collection on the order of picocoulombs (pC).  The 
electrometer also supplies the voltage needed to create an electric field across the 
ionization chamber volume.  Ideally, current leakage would be zero, but in practice, there 
is a tiny (femptoampere) amount of leakage.  Current leakage must be characterized 
during calibration and accounted for during use (Kutcher et al. 1994).   
  The electrometer measurement is displayed in units of charge (pC), which can 
then be converted to current (pA) by dividing the pC reading by the time passed during 
measurement (Δt).  The electrometer reading is then multiplied by the well chamber 
calibration coefficient, which is given in units of mCi pA-1.  (The calibration coefficient, 
C, is actually given in units Air Kerma Strength (U)/pA and then multiplied by a 
conversion factor, where 1 U = 1 uGy m2 hr-1, and 1 mCi (37 GBq) (apparent activity) = 
1.27 U for 125I (Williamson et al. 1991). The apparent activity, Aapp, is “the activity of a 
hypothetical unfiltered point source of the same radionuclide that would give the same air 
kerma rate in air at a reference distance (typically 1 m) along the perpendicular bisector 
of the source.” (IAEA 2005).  This final result is then corrected for atmospheric 
conditions (temperature and pressure variation) and current leakage. 
pC/Δt × Cal C × 1 mCi/(1.27U) × Ne × Ktp = Apparent Activity mCi  (2) 
Where Ne is the electrometer correction factor and Ktp is the correction for non-standard 
temperature and pressure (22ºC and 760 mm Hg, respectively). 
The radioactive source is not always characterized in units of apparent activity.  For 
characterization of therapeutic brachytherapy seeds, Air Kerma Strength is the preferred 
unit, and the step converting U to mCi is removed from equation 2 (Nath et al. 1995).  
125Iodine seed vendor calibration certificates typically include both units. 
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Activity Calibrator 
The activity calibrator, commonly referred to as “dose calibrator”, is a type of 
well ionization chamber designed specifically for assaying radioactive materials used in 
nuclear medicine for imaging or therapy.  It has the same cylindrical shape consisting of a 
heavily shielded outer shell and a thin inner shell with a gas filled chamber in between 
the two shells.  The radioactive source to be assayed is inserted in the center of the inner 
shell, and photon radiation penetrates the inner wall to produce ionization events inside 
the gas chamber.  The primary difference between the activity calibrator and the air-
communicating well chamber involves the gas within the chamber.  The gas chamber of 
the activity calibrator is sealed and filled with pressurized argon.  In order to maintain 
pressurization, the inner shell is thicker than that of air-communicating well chambers.  
This thicker shell greatly lowers the efficiency of the chamber for low energy photons, 
and no photons below 13 keV contribute to measurements made with the activity 
calibrator used in this work (Capintec 1990).  
While the activity calibrator system functions similarly to the air-communicating 
well chamber system, the activity calibrator system is more convenient and expedient to 
use in a clinical setting.  Because the gas chamber is sealed, the temperature and pressure 
within the chamber are not affected by small variations in atmospheric conditions in the 
room (Cherry 2003).  Thus, there is no need for a thermometer and a barometer in normal 
climate controlled laboratory space.  Also, the electrometer and ionization chamber are 
coupled within the activity calibrator.  There is only one component to calibrate, and the 
displayed assay results do not need be adjusted, as the activity calibrator displays results 
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in units of activity.  There is a risk of gas leaking from the chamber over time, which 
would cause inaccurate readings.  Quality assurance performance tests should reveal any 
leakage that has occurred (Carey et al. 2012).  
The activity calibrator displays assay results in units of activity (Bq or Ci), or 
apparent activity in the case of brachytherapy seeds.  This is convenient for 125I RSL seed 
assays for which apparent activity is used in written directives and other documentation.  
For brachytherapy dosimetry calculations, the displayed result must be converted to Air 
Kerma Source Strength (U) with equation 3. 
reading (mCi) x 1.27 U/mCi = Air Kerma Source Strength (U)   (3) 
The 125I brachytherapy seed vendor typically provides calibration data in both units. 
Ionization Chamber Survey Meter 
Ionization chamber survey meters, commonly referred to as exposure rate meters 
or dose rate meters, are based on the same underlying physics as the well-type ionization 
chambers.  Given the survey meter’s designed general purpose, portability and 
ruggedness take priority over accuracy (±10% at a specific calibrated energy) (Fluke 
2013). The survey meter is a hand-held instrument and as such, must be made out of low-
weight materials.  It is not designed to envelope a radioactive source, but instead it is 
placed inside of a radiation field in order to measure the exposure rate for verification of 
safety and regulatory compliance.  The chamber itself is much smaller than that of well-
type ionization chambers.  The electronics (voltage supply, electrometer circuit, batteries) 
are built into the same housing as the ionization chamber, and as such are also smaller 
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than the electronic components of well-type ionization chambers.  Survey meter 
ionization chambers can also be pressurized for sensitivity to lower levels of radiation.  In 
general, desirable fill gas properties are the same for both hand-held ionization chambers 
and well-type ionization chambers, and either air or a high-Z noble gas (typically argon) 
is used (Bushberg et al. 2002). 
 One of the challenges in using an ionization chamber survey meter for 
source assay procedures lies in utilizing a consistent geometry.  For any calibration, the 
reproducibility of the geometry is necessary for accuracy.  This is much easier with well-
type ionization chambers, where the source is placed in the center of the well with a 
designated source holder.  Thus, only one component must be placed accurately each 
time, and ideally the source holder is designed to slide in place with no room for 
variation.  For the survey meter, both the meter and the source must be placed accurately 
utilizing a template, source holder, clamps, etc.  The set-up must be carefully recreated 
for each future radioactive source assay.  Thus, achieving acceptable accuracy and 
reproducibility in brachytherapy seed calibrations could be challenging when using an 
ionization chamber survey meter (Svensson et al. 1994). 
An ionization chamber survey meter cannot be calibrated to display a reading in 
units of activity or other unit that can be directly converted to activity.  Instead, the 
source exposure rate constant must be determined so that the displayed reading units of 
exposure rate in mR hr-1 (µSv hr-1) can be converted to activity in units of mCi (GBq).  
Calibration of the survey meter then consists of determining a calibration factor for each 
radionuclide source, composition, form factor and geometry that will be assayed with the 
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survey meter.  While it would not be practical to determine a calibration coefficient for 
general field use (varying radionuclides and constantly changing geometry), it is 
theoretically possible to create a consistent geometry for assaying a specific radioactive 
source (e.g. a brachytherapy seed).   
NIST Traceability 
The National Institute of Standards and Technology (NIST), founded in 1901 
(originally named the National Bureau of Standards), provides standard weights and 
measurements for the United States (Cochrane 1974; Passaglia et al. 1999).  NIST, along 
with similar institutions in other countries, provides an array of products and services that 
promote the consistent, accurate, and effective use of technology in research and industry 
(IAEA 2002).   One vital service provided by NIST is the creation (via calibration, not 
actual source manufacturing) of reference standard sources for radiation measurements 
along with the framework (a calibration chain) for assuring calibration of radioactive 
sources and instruments for characterizing radiation is performed in a consistent, 
accurate, and reproducible manner.  In this function, NIST is considered a Primary 
Standards Dosimetry Laboratory (PSDL).  The Physical Measurement Laboratory (PML) 
provides radiation source and instrument calibration services that directly quantify their 
relationship to SI (Système International d’Unités) units with a specified uncertainty and 
confidence level.  A source or instrument that has been calibrated at the NIST PML is 
said to have “direct NIST traceability” (Hendee et al. 2005).  In practice, ionization 
chambers and other instruments and standards owned by end users are not calibrated by 
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NIST.  Instead, they have been calibrated by a Secondary Standards Dosimetry 
Laboratory (SSDL).  An SSDL receives calibrations of its standards and calibration 
instruments from NIST and must go through an accreditation process.  The AAPM) is the 
accrediting body in the United States) before providing calibration services for end users.  
All of the SSDL sites must participate in regular intercomparison tests (Hendee 2005).  
The instruments and radiation sources calibrated by an SSDL are said to be secondary 
standards with calibrations directly traceable to NIST.  Ionization chambers with directly 
traceable calibrations are recommended for calibration of radioactive brachytherapy 
seeds upon receipt from the seed vendor (Butler 2008).  The source strength 
measurements will then have secondary traceability to NIST. 
The system of SSDLs was developed by the AAPM in the 1970s to address 
several limitations with the previous method of contracting NIST directly.  With the 
growing number of hospitals needing accurate and precise dosimetry calibration services, 
more laboratories were needed to meet the demand within a reasonable time frame.  The 
SSDLs would be run independently from NIST (but with direct NIST traceability), and 
would focus on medical dosimetry calibration services.  The SSDL system would be 
designed by AAPM to meet the needs of the medical physics community and to provide a 
technical resource for the AAPM.    There are three SSDLs in the United States.  They 
are given the title Accredited Dosimetry Calibration Laboratory (ADCL) and are 
accredited by the AAPM.  One of the three ADCLs is housed within MDACC.  The other 




Nuclear Regulatory Commission (NRC)  
 Federal regulations relevant to the medical use of radioactive material are found 
in the code of federal regulations part 35 (10 CFR 35), Medical Use of Byproduct 
Material (U.S. NRC 2015c).  Subpart G, Sealed Sources for Diagnosis, would appear to 
be a relevant section, but it is very brief and deals mostly with training and authorization.  
Subpart F, Manual Brachytherapy, gives a more thorough list of requirements and 
expectations for the use of sealed sources in patients.  Section 35.400, Use of sources for 
manual brachytherapy, states that the regulations contained in 35.400 are intended for 
therapeutic use of sealed sources.  While RSL procedures are not considered therapeutic, 
Subpart F provides the only relevant NRC requirements for radioactive seed source 
strength verification and dosimetry system requirements.  Subpart K, Other Medical Uses 
of Byproduct Material or Radiation from Byproduct Material (10CFR35.1000), permits 
the RSL procedure (or any other sealed source use not covered in Subparts D-H) 
provided an application for such use has been submitted and approved by the NRC.  
According to the NRC Sealed Source and Device Registry, 125I use for localization of 
nonpalpable lesions is explicitly authorized under 10CFR35.1000 (U.S. NRC 2015b). 
BRACHYTHERAPY SEED CALIBRATION 
 Section 35.432, Calibration Measurements for Brachytherapy Sources, is the 
primary NRC reference for brachytherapy seed source strength verification.  This section 
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requires the licensee to measure either the source strength or activity of the source by 
following “published protocols accepted by nationally recognized bodies” (U.S. NRC 
2015c).  These measurements must be performed with a dosimetry system that has been 
either calibrated with an appropriate NIST traceable source or calibrated by an ADCL 
within the previous 2 years.  The licensee can extend this calibration period if multiple 
dosimetry systems are owned.  In this case, the dosimetry system can wait 4 years for 
calibration as long as it has been inter-compared within 18-30 months of initial 
calibration with a second dosimetry system that has been calibrated within the previous 2 
years and the dosimetry system (the system that is waiting 4 years for calibration) 
calibration factor has not changed by more than 2%.  If these conditions are met, the 
original calibration factor (from actual NIST traceable calibration) will continue to be 
used.  The air-communicating well-type ionization chamber is a commonly used 
brachytherapy dosimetry system that is calibrated according to this subsection of the 
federal regulations.  Pressurized well-type ionization chambers, specifically designed for 
brachytherapy seeds, are also used for this purpose.  The typical activity calibrator used 
by nuclear medicine departments is not designed specifically for brachytherapy seeds, 
and the calibration of such is governed by a different subsection of the federal code.  The 
licensee is also allowed to use the source manufacturer’s calibration, provided the 
manufacturer used a dosimetry system with NIST traceable calibration or have seeds 
calibrated at an ADCL in lieu of performing in house calibration measurements.  
 The NRC Medical Licensee Toolkit (Licensing Guidance), Iodine-125 and 
Palladium-103 Low Dose Rate Brachytherapy Seeds Used for Localization of Non-
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Palpable Lesions, specifically states that 125I brachytherapy seeds used for RSL “are not 
regulated under 10CFR35.400 or the equivalent Agreement State regulations” (U.S. NRC 
2015a).  Instead they are regulated under 10CFR.1000 “Other medical uses”.  According 
to the Medical Licensee Toolkit, seed activity will be verified prior to administration with 
an instrument calibrated according to nationally recognized standards or manufacturer’s 
instruction.   
ACTIVITY CALIBRATOR 
 The pressurized well-type chamber, or activity calibrator, used by nuclear 
medicine departments for assaying unsealed byproduct material before it is administered 
to a patient, must also be calibrated and maintained in accordance with the regulations.  
This is stated in Subpart C, General technical requirements, but the process for doing so 
is not given.  Instead the licensee is instructed to “calibrate the instrumentation in 
accordance with nationally recognized standards or the manufacturer’s instruction” 
(10CFR35.60).  
A recommended model activity calibrator calibration procedure is described in the 
NRC Regulatory Guide 10.8, Guide for the Preparations of Applications for Medical Use 
Programs.  The model procedure given in Appendix C of NRC Regulatory Guide 10.8 is 
essentially a full quality control (QC) program as opposed to a one-time calibration.  The 
model procedure consists of daily constancy tests, quarterly linearity tests, geometry at 
installation, and annual accuracy tests.  Although the regulatory tolerances are  ±10% (for 
each of the tests), Regulatory Guide 10.8 recommends setting an internal procedural 
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tolerance at  ±5% in order to facilitate corrective actions before approaching regulatory 
tolerances (ANSI 1986; U.S. NRC 2008).   
IONIZATION CHAMBER SURVEY METER 
 The regulatory requirements for survey meter calibration are covered in 
10CFR35.61.  Note that these instructions are for general survey meter use, and will not 
be sufficient for the purpose of brachytherapy source strength verification.   Survey 
meters must be calibrated before first use, annually, and after repairs.  The calibration 
process for survey meters leaves a lot of room for error.  Two calibration points are 
chosen per scale.  The survey meter is adjusted so that the reading is close to the 
expected, theoretical response at the two points.  The difference between the indicated 
reading and the theoretical calculation must be less than 20% for each calibration point.   
 NRC Regulatory Guide 10.8 gives more specific instructions within the Appendix 
B model survey meter calibration procedure.  The calibration source must be a NIST 
traceable point source with no more than 5% uncertainty.  The source should emit 
radiation of the same type and similar energy to that of the radiation field in which the 
detector will be used, and should be of sufficient strength.  Regulatory Guide 10.8 
recommends a more conservative error margin of 10% for any one particular calibration 
point.  Also, for digital readout survey meters that automatically rescale, only one 
calibration point is needed for each decade, and two calibration points are needed on at 
least one decade.  Recommended daily QA checks only include constancy tests, which 
consist of taking an exposure rate reading with a known check source that was also 
measured at the time of calibration. 
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Department of State Health Services (DSHS)  
 Texas state regulations relevant to medical radioactive material are found in the 
Texas Administrative Code part 289.256 (25TAC289.256), Medical and Veterinary Use 
of Radioactive Material (DSHS 2015).  The wording is essentially verbatim from the 
NRC regulations for all aspects of low dose rate manual brachytherapy seed strength 
verification.  Subsections 289.256(rr)-289.256(ww) give the requirements and 
expectations for the use of manual brachytherapy sources in patients.  Subsection 
289.256(rr), Use of Sealed Sources for Manual Brachytherapy, states that the regulations 
contained within 289.256(rr) are intended for therapeutic use of sealed sources.  While 
RSL procedures are not considered therapeutic and as such, this application is should fall 
under regulations analogous to NRC 10CFR35 Subpart K, Other Medical Uses of 
Byproduct Material or Radiation from Byproduct Material (10CFR35.1000), subsections 
289.256(rr)-289.256(ww) provide the only relevant DSHS regulations for radioactive 
seed source strength verification and dosimetry system requirements.  No analogue to 
10CFR35.1000 exists in the DSHS regulations, but there is reference to the Sealed 
Source and Device Registry, which lists localization of nonpalpable lesions as an 
authorized use (governed by NRC regulations) of 125I brachytherapy seeds. 
BRACHYTHERAPY SEED CALIBRATION 
 Subsection 289.256(ww), Calibration Measurements of Brachytherapy Sealed 
Sources, is the primary reference for brachytherapy seed source strength verification.  
This section requires the licensee to measure either the source strength or activity of the 
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source by following “published protocols accepted by nationally recognized bodies”.  
These measurements must be performed with a dosimetry system that has been either 
calibrated with an appropriate NIST traceable source or by an ADCL within the previous 
2 years.  The licensee can extend this calibration period if multiple dosimetry systems are 
owned (and kept in calibration) by following the same steps outlined in the NRC Code of 
Federal Regulations. 
 The DSHS Regulatory Guides do not provide any information specific to RSL 
procedures.  There is a Regulatory Guide for medical licensees titled Regulatory Guide 
3.1 – Guide for the Preparation of License Applications for the Medical Use of 
Radioactive Material (DSHS 2012).  It is very similar to the NRC Regulatory Guide 10.8.  
There is no DSHS analogue to the NRC Medical Licensee Toolkit for RSL.  Without any 
specific DSHS regulations to address RSL procedures, licensees much follow the NRC 
guidelines. 
ACTIVITY CALIBRATOR 
 The pressurized well-type chamber, or activity calibrator, used by nuclear 
medicine departments for assaying unsealed radioactive material, must also be calibrated 
and maintained in accordance with the regulations, and the general requirements for this 
process are explained in subsection 289.256(v).  The calibration must be performed in 
accordance with nationally recognized standards or manufacturer’s instructions.  This 
section of the regulations specifically requires a minimum of tests for accuracy, 
constancy, linearity, and geometry dependence.  An ongoing QC program is also 
required.  Accuracy must be performed once per year, constancy daily before use, 
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linearity quarterly, and geometry dependence at installation and after relocation and 
repair. 
 Regulatory Guide 3.1 – Guide for the Preparation of License Applications for the 
Medical Use of Radioactive Material recommends that the licensee follow ANSI, NRC, 
or manufacturer’s instruction.  A recommended model activity calibrator calibration 
procedure is described in Appendix I of Regulatory Guide 3.1.  It is essentially the same 
model procedure given in the NRC Regulatory Guide 10.8.  The model procedure is a full 
QC program as opposed to a one-time calibration.  The model procedure consists of daily 
constancy tests, quarterly linearity tests, geometry at installation, and annual accuracy 
tests.  As was the case with the NRC, the regulatory tolerances are ±10%, Regulatory 
Guide 3.1 recommends setting an internal procedural tolerance at ±5% in order to 
facilitate corrective actions before approaching regulatory tolerances.  
IONIZATION CHAMBER SURVEY METER 
The regulatory requirements for survey meter calibration are covered in 
289.256(w).  This subsection is verbatim from NRC 10CFR35.61.  Survey meters must 
be calibrated before first use, annually, and after repairs.  Two calibration points are 
chosen per scale.  The survey meter is adjusted so that the reading is close to the 
expected, theoretical response at the two points.  The difference between the indicated 
reading and the theoretical calculation must be less than 20% for each calibration point.  
Regulatory Guide 3.1 does not provide a model survey meter calibration process.  
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American Association of Physicist in Medicine  
 “The AAPM is a scientific and professional organization, founded in 1958, 
composed of more than 8000 scientists whose clinical practice is dedicated to ensuring 
accuracy, safety and quality in the use of radiation in medical procedures such as medical 
imaging and radiation therapy.  One of the primary goals of the AAPM is the 
identification and implementation of improvements in patient safety for the medical use 
of radiation in imaging and radiation therapy” (AAPM 2015).  The AAPM is a nationally 
recognized body that regularly publishes recommended procedures and protocols in the 
form of AAPM Reports.  There are six reports that provide recommendations of interest 
for this work (i.e. brachytherapy seed, well chamber and ionization survey meter 
calibration and quality assurance).   
BRACHYTHERAPY SEED SOURCE STRENGTH VERIFICATION 
 The first published recommendations for brachytherapy seed source strength 
calibration are printed in AAPM Report #13, Physical Aspects of Quality Assurance in 
Radiation Therapy.  In this report, brachytherapy seed calibration by intercomparison 
with a standard source is emphasized over relying on the seed manufacturer’s calibration 
or instrument calibration factor (Svensson et al. 1984).  Furthermore, the report does not 
give preference to any particular instrument type, as long as the same instrument is used 
for each seed calibration.  The activity calibrator typically found in nuclear medicine 
departments is listed as a perfectly acceptable instrument for this purpose.  Regardless of 
chosen instrument the measurement reproducibility should be within ±2%.  The user 
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should characterize the instrument in terms of scale factor and linearity of all scales or 
radionuclide settings that might be changed for different seeds, ion collection efficiency, 
geometry and length dependence, thickness, and energy dependence.   
 In the source intercomparison process, one source from a manufactured lot to be 
used in a clinical setting is chosen to be the standard source.  This standard source is sent 
to an ADCL for calibration.  (The ADCL is not actually mentioned in Report #13.  
Instead the National Bureau of Standards, the predecessor of NIST, is referenced.)  Once 
the standard source has a NIST traceable calibration, it is placed in the clinic’s calibration 
instrument in the same geometry as the other clinical sources.  The readings are 
compared in order to determine the activity (source strength or Air Kerma Strength) of all 
sources.  The NIST traceable calibration source can also be used for ongoing instrument 
quality assurance tests.  When the radionuclide would require frequent replacement due 
to a short half-life, additional steps must be taken in order to facilitate future seed batch 
calibration after the standard source has decayed.  After the standard source has been 
calibrated at an ADCL, the calibration must be transferred to a long-lived reference 
source.  AAPM Report #13 recommends two different methods of accomplishing the 
calibration transfer (Svensson et al. 1984).  In the first method the instrument is 
calibrated with the standard source.  The reference source is then assayed with the 
instrument and used as a QA source before each subsequent seed calibration.  In the 
second method both reference and standard sources are assayed in the instrument, and the 
ratio of the instrument responses is used to calculate a correction factor in terms of the 
reference source.    
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 AAPM Report #46, Comprehensive QA for Radiation Oncology, written 10 years 
later, updates and supersedes AAPM Report #13 (Kutcher et al. 1994).  This report also 
emphasizes independent verification of source strength of brachytherapy seeds prior to 
administration in a patient.  It is recommended that this calibration be accomplished 
through a procedure having either direct traceability (source calibrated by NIST or an 
ADCL) or secondary traceability (intercomparison with a directly traceable source of the 
same design or source calibration with a directly traceable instrument).  The discrepancy 
for a batch should not be greater than 3% on average and not greater than 5% for a single 
source.  The ideal calibration instrument measurement reproducibility is better than 2%, 
and the activity calibrator (well chamber) is given as an appropriate instrument.  Again 
the user should characterize the instrument in terms of scale factor and linearity, ion 
collection efficiency, geometry and length dependence, thickness, and energy 
dependence.  A calibration/QA redundancy system consisting of instrument and source 
intercomparison is also introduced in Report #46.  One example is a three-component 
redundancy system consisting of the seed calibration instrument, a standard source of the 
same radionuclide that will be calibrated with the instrument, and a second long-lived 
standard source of a different radionuclide.  The intercomparison redundancy check is 
performed each time a seed is calibrated.  Report #46 recommends a three-components 
system, although two-component systems are allowed.  
 AAPM Report #51, Dosimetry of Interstitial Brachytherapy Sources, serves 
primarily to give the medical physicist a dose calculation formalism for interstitial 
brachytherapy.  Report #51 emphasizes source strength measurements be made in units 
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of Air Kerma Strength, but it does not make any recommendations relating to the actual 
calibration process itself.  AAPM Report #59, Code of Practice for Brachytherapy 
Physics, repeats the source strength calibration recommendations from Report #46 but 
with use of the word “shall” when referring to verification of manufacturer source 
calibration with secondary (or direct) traceability.  This indicates a legal requirement that 
a licensed medical physicist performs this task for each source (or a single sample from a 
batch) before administration in a patient (Nath et al. 1997).  The next AAPM Report that 
discusses brachytherapy source calibrations, AAPM Report #84, Update of AAPM Task 
Group No. 43 Report: A Revised AAPM Protocol for Brachytherapy Dose Calculations, 
reiterates previous brachytherapy source calibration recommendations, but it never uses 
the word “shall” in regards to secondary traceability.  Instead “recommends” and 
“should” are used (Rivard et al. 2004).  AAPM Report #98, Third-Party Brachytherapy 
Source Calibrations and Physicist Responsibilities: Report of the AAPM Low Energy 
Brachytherapy Source Calibration Working Group, summarizes the various AAPM 
reports regarding brachytherapy source calibration and addresses the practice of allowing 
a third-party (not the source manufacturer or end user) to calibrate the brachytherapy 
source.  Essentially, AAPM Report #98 reinforces AAPM Report #59.  The institution 
administering brachytherapy seeds into patients is expected to verify the manufacturer 
source calibration using a system with secondary traceability.  The words “shall” and 
“must” are used in regards to secondary traceability, which indicates requirements for 
regulatory compliance.  AAPM Report #98 places responsibility for source strength 
calibration to the institutional (administering brachytherapy seeds to patient) medical 
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physicist regardless of any third-party brachytherapy source calibration that has been 
performed.   
WELL CHAMBER CALIBRATION AND QA 
The first AAPM-recommended brachytherapy source calibrator QA program 
appears in AAPM Report #46.  Specific QA tests, tolerances and frequencies are listed 
for the ionization well chamber.  There are two categories of testing frequencies: 1. initial 
use or following malfunction and repairs, and 2. each use or ongoing evaluation.  The 
first category includes ADCL calibration (directly traceably to NIST), precision, 
linearity, collection efficiency, geometry, energy dependence.  The second category 
includes redundant checks and tests for leakage of pressurized chamber gas.  The 
recommended tolerance is 1% coefficient of variation for linearity and collection 
efficiency, and it is 2% coefficient of variation for precision and redundant checks.  All 
other tolerances simply require documentation and application of a correction factor.  For 
the redundancy checks, a three-component redundancy system is preferred (Kutcher et al. 
1994).   
AAPM Reports #59, #84 and #98 support the same well chamber QA program 
outlined in AAPM Report #46.  AAPM Report #84 also gives two different calibration 
schemes that assure secondary traceability.  In the first scheme, the well chamber is sent 
to an ADCL (on two year intervals) for a directly traceable calibration.  Alternatively, a 
source calibrated by NIST or an ADCL (directly traceable source calibration) can be used 
to calibrate a well chamber, giving it a calibration with secondary traceability.  In either 
method, this well chamber can then be used to verify the manufacturer calibration of a 
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brachytherapy source.  It is recommended that the user verify that the total uncertainty in 
the well chamber calibration (secondary traceability) is comparable to that of a directly 
traceable well chamber calibration (Rivard el al. 2004). 
RADIONUCLIDE CALIBRATION AND WELL CHAMBER CALIBRATION AND QA IN 
DIAGNOSTIC IMAGING 
 
AAPM Report #181: Selection, Use, Calibration, and QA of Radionuclide 
Calibrators in Nuclear Medicine, is the only AAPM report that gives a full treatment to 
well chamber radionuclide measurements in a nuclear medicine (therapy and diagnostic) 
setting.  Although most nuclear medicine radionuclide doses are in unsealed form, it is 
relevant to consider the acceptable levels of uncertainty, as this represents the most 
common example of non-therapeutic radionuclides being administered to a patient.  The 
report refers specifically to pressurized well-type ionization chambers commonly referred 
to as radionuclide or dose calibrators.  AAPM Report #181 recommends that assay 
activities be ±10% (total uncertainty budget) of prescribed activities for diagnostics 
(Carey et al. 2012).  For short lived, unsealed radioactive material such as technetium-
99m 99mTc and fluorine-18 18F uncertainty in exact administration time and amount of 
drug that is delivered internal to the patient’s body, along with calibration accuracy, 
contribute to total uncertainty in administered dose.  In the case of sealed radioactive 
material (e.g. 125I brachytherapy seeds) the uncertainty in calibration accuracy and 
implant location are the primary sources of uncertainty.  A “properly calibrated, operated, 
and maintained” activity calibrator should provide assays within acceptable accuracy 
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tolerances.  Note that AAPM Report #181 recommends not using a radionuclide activity 
calibrator for sealed sources that will be used for brachytherapy.  The report references 
AAPM Report #98 for this statement, but no equivalent statement exists in Report #98.  
AAPM Report #98 only states that “the institution shall have a system for measuring 
source strength with secondary traceability for all source types used in practice” (Butler 
et al. 2008). 
 AAPM Report #181 offers a well chamber calibration scheme that is more 
flexible than that of well chambers used for brachytherapy seed calibration.  Unlike well 
chambers used for sealed brachytherapy sources, activity calibrators are usually given a 
factory calibration with specific calibration coefficient settings (referred to as cal 
numbers) for a range of commonly used radionuclides in a specific geometry, as well as 
source composition and form factor.  The factory calibration scheme starts with a master 
well chamber calibrated with a few NIST traceable sources.  From these standard source 
assays, a response-energy curve is created, and calibration settings are determined for 
other radionuclides based on interpolation or Monte Carlo simulation.  The calibration is 
then transferred to the production well chambers that are purchased and used by medical 
facilities, nuclear pharmacies, etc.  The end user can perform a calibration of the well 
chamber as well using an appropriate NIST traceable standard.  AAPM Report #181 
references three classes of well chamber calibration, the secondary standard radionuclide 
calibrator (SSCR), the reference radionuclide calibrator (RRC) and the production 
radionuclide calibrator (field instrument).  The difference lies in the traceability pathways 
and use.  The SSCR is calibrated with a primary NIST traceable standard and is used to 
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calibrate secondary standard sources that are then used to calibrate field instruments 
(Zimmerman et al. 2000).  If a field instrument is later calibrated with a NIST traceable 
standard source, then it can become a SSCR.  The RRC calibration has secondary 
traceability and is also used to calibrate field instruments, but it is not used to calibrate 
secondary standards (nor is it used in the field).  The recommended activity calibrator 
assay accuracy tolerance for low energy photon emitters (<100 keV) is 10% with field 
instruments and 5% with SSCR and RRC. 
 During the well chamber calibration process, changes and adjustments are not 
made to the well chamber itself (unless repair is needed).  Instead, a standard source is 
assayed with the well chamber, the response is recorded and a calibration coefficient is 
calculated in order to account for the difference between well chamber response 
(displayed on instrument direct readout or electrometer) and actual source activity.  This 
calibration coefficient is then applied to all future measurements of the same source type 
(radionuclide and physical design).  When working with activity calibrators, the 
instrument performs the calculations and automatically assigns varying calibration 
coefficients to a series of calibration settings (cal numbers).  The user simply presses a 
button to change the calibration setting until the displayed activity matches the actual 
activity of the standard source.  This calibration setting is then selected for all future 
measurements of the same source type (radionuclide, geometry, etc.).  Even with a 
calibrated well chamber, there are several additional sources of error.  One common error 
occurs when the assayed source geometry (location, encapsulation/container material/ 
size/volume) differs from that of the primary standard.  Then the assigned calibration 
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setting could potentially yield inaccurate results.  Other sources of error include errors in 
calibration of standard sources, variation in chamber gas pressure, backscatter within the 
well, and the accuracy and linearity of the system electronics (Carey et al. 2012).  
Activity calibrators tend to be less accurate when used to assay low-energy (<100 keV) 
photon emitters, such as 125I.  In this energy range, photon attenuation in the source 
holder and inner well chamber wall is much greater and more dependent on variation in 
material. 
 Recalibration recommendations vary with well chamber manufacturers.  
Typically this occurs after damage and repairs, long periods of not being in use, or when 
the instrument fails a QA test, although periodic recalibration is recommended, in 
general, in order to maintain optimal performance.  The QA program recommended in 
AAPM Report #181 includes 11 performance tests; physical test, system electronics test, 
clock accuracy, high voltage, zero adjust, background response/contamination check, 
check source (constancy and relative instrument response), accuracy test, reproducibility 
(precision), system linearity, and supplier equivalence (Carey et al. 2012).  All 11 tests 
should be performed during acceptance, annually and after repair.  All tests except for 
accuracy, reproducibility, system linearity, and supplier equivalence should be performed 




DESCRIPTION OF HOW PROBLEM WAS SOLVED 
125ISeed Calibration 
 Eight total 125I interstitial brachytherapy calibration seeds (model number IAI-
125A, IsoAid, 7824 Clark Moody Boulevard, Port Richey, FL 34668) were calibrated for 
use in determining the appropriate (for this specific type of 125I source) activity calibrator 
activity assay setting (calibration number) and survey meter calibration factor, and for 
assessing the associated uncertainty in 125I seed assays made with these radiation 
detection systems.  Each seed was manufactured and calibrated by IsoAid as part of a 
RSL seed lot for use in clinical RSL procedures at MD Anderson.  Initially, the six most 
recent (highest activity) available seeds were chosen, and two additional seeds were 
added midway through the project when new RSL seed lots arrived.  One of the original 
vendor calibration certificates is shown in Appendix A.  The 125I seed with the highest 
activity (from original group of six, excluding the seventh seed) was sent to the MDACC 
ADCL for a NIST traceable calibration. The ADCL calibration was in units of Air Kerma 
Strength (U), and it was necessary to divide this value by the conversion factor 1.27 U 
mCi-1 (for 125I seeds) to obtain the apparent activity in mCi (Nath et al. 1995).  The seeds 
were also examined for anisotropy in a qualitative fashion with a survey meter and the 
effect of which was tested on the well chamber to determine if anisotropy (if observed) 
would alter outcome of the seed calibration.  The test on the well chamber consisted of 
assaying Seed 1 in the HDR1000 for 20 trials of 15 s each and repeating the process with 
the seed rotated ~90˚.  Only the seed was rotated, not the seed holder.  The accumulated 
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charge (pC) for each set of trials was compared in terms of maximum reading, minimum 
reading, percent difference between maximum and minimum, average reading, standard 
deviation and coefficient of variation.  
Only one seed (referred to as “Seed 1” from here on) received an ADCL 
calibration.  The other six seeds were each calibrated with an air-communicating well-
type ionization chamber (model HDR1000, Standard Imaging Inc., 3120 Deming Way 
Middleton WI 53562).  In order to obtain the HDR1000 calibration coefficient in units 
mCi pA-1 for 125I seeds (specifically for IsoAid M/N: IAI-125A) and determine the 
optimal counting time to assure satisfactory levels of uncertainty, Seed 1 was assayed a 
total of 60 times.  Three sets of 20 assays were performed with charge collection times of 
15 s, 30 s, and 60 s.  Each set of 20 assays was grouped into subsets of 5, 10, and 20 
measurements and averaged in order to investigate the effect of number of trials on 
precision (i.e. the average of 5 trials vs. the average of 10 trials vs. the average of 20 
trials).  This sums to a total of 21 measurement data permutations (four sets of five trials, 
two sets of 10 trials and one set of 20 trials for each count time of 15 s, 30 s and 60 s) 
within the 60 total individual measurements.  Once the well chamber calibration 
coefficient was determined, the well chamber was used to assay the other five seeds.  The 
same procedural combination of 60 measurements was used to assay each of the five 
seeds and analyze the precision and reproducibility of this process for the various 
combinations of experiment parameters.  The entire seed calibration process (except the 
initial Seed 1 ADCL calibration) was repeated two more times on different days in order 
investigate procedural reproducibility in terms of both time and seed radioactive decay.  
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On each day, a barium-133 (133Ba) source was used to perform a constancy check of the 
HDR1000.  Five well chamber calibration coefficients (obtained from assays of Seed 1 
on five different days) were compared to the original ADCL calibration of the well 
chamber (May 2014) and differences tested for statistical significance.  The first 
calibration coefficient obtained with the first day of Seed 1 measurements was used 
throughout this work in all subsequent apparent activity measurements. 
Activity Calibrator Calibration 
 The activity calibrators commonly used by nuclear medicine clinics are designed 
for assay of unsealed radioactive material in a vial, syringe or capsule.  While these 
instruments are capable of measuring the radiation emitted from sources of various 
shapes and forms (solid, liquid, gas), they do not come with any standard apparatus for 
positioning a brachytherapy seed in a consistent geometry.  For this investigation, two 
different geometry configurations were created.  The first configurations consisted of the 
source holder from the HDR1000 and one of the vial/syringe inserts, commonly referred 
to as “dippers”, that came with the activity calibrator (CRC-15R, Capintec, Inc., 6 Arrow 
Road Ramsey, NJ 07446) used in this investigation.  The seed was placed in the 
HDR1000 single seed holder (model 70016, Standard Imaging Inc., 3120 Deming Way 
Middleton WI 53562), which was then inserted into the dipper.  The second geometry 
configuration consisted of the dipper and the ~7.5 ml glass vial that the seed was shipped 
in.  The seed was randomly placed on the bottom of the vial, and the vial was placed at 
the bottom center of the dipper.  Both geometry configurations are shown in Figure 2.  
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Whereas it was not possible for the 125I seed to move significantly inside the HDR1000 
single seed holder, the seed could easily slide to various positions on the bottom of the 
glass vial.   The seeds were 4.5 mm in length, and the bottom of the glass vial was 
circular with an inner diameter of 14 mm.  Measurements were also performed with a 
second dipper and glass vial to assess reproducibility with regards to system parts that are 
likely to be exchanged over time. On two separate days, each seed was placed in the 
activity calibrator utilizing the two geometry configurations described above.  The cal 
number was varied until the correct apparent activity was displayed.  Each cal number 
and apparent activity was recorded. The process was repeated with a second glass vial, a 
second dipper and a second HDR1000 single seed holder, and the same cal numbers 



















   
 
 
     
 
 
Figure 2.  Geometry configurations for the glass vial and the HDR1000 single seed 
holder.  The dippers were then slid into the activity calibrator. 
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In order to assess uncertainty in 125I seed assay results due to inconsistent 
measurement geometry, an experiment was devised in which seed assays were performed 
under conditions of consistent (as much as possible) geometry and intentionally 
inconsistent geometry.  For the case of consistent geometry, Seed 1 was inserted into the 
activity calibrator 25 times (five sets of five trials) per geometry configuration (50 total 
trials) with attention paid to accurately reproducing the geometry each time.  For each set 
of five trials the glass vial or HDR1000 single seed holder was placed in the center on the 
bottom of the activity calibrator dipper.  Tape was used to assure that the geometry did 
not change in between trials.  After every five sets of insertion/removal of the seed, the 
geometry configuration was taken apart and reassembled to investigate the 
reproducibility of this “consistent” geometry configuration.  For each trial the cal number 
was varied until the correct apparent activity was displayed.   
For the case of inconsistent geometry, Seed 1 was then inserted into the activity 
calibrator 35 times per geometry configuration while the location of the glass vial or 
HDR1000 single seed holder was intentionally shifted to various off-center locations on 
the bottom of the activity calibrator dipper between each trial.  Seven different specific 
locations were chosen, and each set of seven trials was repeated five times. The locations 
are shown in Figure 3.  For each trial the cal number was varied until the correct apparent 
activity was displayed.  The maximum and minimum cal numbers were identified for 
each set of seed measurements (consistent geometry and inconsistent geometry).  These 
cal numbers were then used to assay the seed.  For each cal number the seed was assayed 
five times and averaged.  The percent difference between the apparent activity results 
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from consistent geometry and inconsistent geometry were calculated as well as the 
percent error in the apparent activity results obtained from the maximum and minimum 































Figure 3. The seven glass vial locations in this experiment included the offset location 
shown, three other offset locations at 90º intervals, the glass vial lying horizontally, as 
shown, the glass vial lying horizontally, but rotated 90º and a centered, upright position 
(as in the “consistent geometry” configuration).  The four 90º offset locations and the 
centered, upright-position were also utilized for the HDR1000 single seed holder.  The 
horizontal positions were not possible due to the height of the seed holder. 
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 All seven seeds were used to determine an appropriate cal number for the activity 
calibrator.  Utilizing both geometry configurations under conditions of “consistent” 
geometry as described earlier, Seed 1 was measured on five different days spanning a 
period of six weeks to determine an appropriate cal number.  For each measurement, four 
different apparent activity values were utilized.  The ADCL calibration was considered 
the most accurate and was thus assumed to be the true apparent activity of the seed.  The 
vendor provided apparent activity was utilized for the purpose of comparison (and in 
practice, after verification of seed apparent activity, it is the vendor stated apparent 
activity value that is actually used for comparison).  For both of these cases, the apparent 
activity values were decayed to the exact time of measurement (to the minute).  The last 
two apparent activity values were based on the vendor provided apparent activity but 
under the assumption that the calibration time was only accurate to the nearest day 
instead of minute.  This was done to assess the variation in cal number (and final 125I seed 
assay) that might arise from only entering the vendor calibration and experimental 
measurement days (and not including the hour or minute) into the calculation 
spreadsheet.  To account for this, the vendor calibration time was offset by ±12 hr, which 
represents a reasonable worst case.  Although, in theory the time could be off by up to 24 
hr, the extremes (i.e. vendor calibration very early in the morning and institution assay 
late at night or vice-versa) were considered unlikely to occur in practice.   For each 
apparent activity value, the activity calibrator cal number was varied until the correct 
apparent activity appeared on the display.  This resulted in eight calibration numbers 
(four per geometry configuration) per seed per day, or 32 total calibration numbers (with 
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many duplicate calibration numbers) per seed.  This process was then repeated for each 
of the six other seeds also over a period of two months.  Constancy tests were performed 
periodically with a 137Cs vial source for one month and then later with an 125I seed over a 
period of one month.  The activity calibrator also received independent constancy tests 
and an annual accuracy test, which can be found in Appendix B. 
 The various activity calibrator cal numbers were examined in order to identify 
significant sources of uncertainty.   Each procedural step was applied separately to the 
glass vial geometry configuration and the HDR1000 seed holder geometry configuration.  
It was not reasonable to have an intercomparison between the cal numbers for the two 
geometry configurations, as the activity calibrator response is highly sensitive to 
geometry difference.  For each seed apparent activity (experimental or ADCL calibration, 
vendor calibration, vendor -12 hr, vendor +12 hr) the minimum and maximum cal 
numbers were identified and the mean cal number was calculated (and then rounded to 
whole number since fractional cal numbers do not exist).  The standard deviation of the 
cal numbers was calculated, which allowed cal numbers to be identified at ±1σ and ±2σ 
from the mean.  For each 125I seed the percent difference between the maximum and 
minimum cal numbers (based on experimental or ADCL 125I seed calibration) over the 
five trials was also calculated. 
 While variation in activity calibrator cal number is interesting to consider, the 
ultimate goal of this project is to assess the ability of a activity calibrator to accurately 
assay unknown 125I seeds.  In order to quantify this, Seed 1 through Seed 4, Seed 7, and a 
new seed, Seed 8 (replaced the oldest seed, Seed 6, due to low activity), were assayed in 
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the activity calibrator over the various ranges (mean, maximum, minimum, ±1σ and ±2σ 
from the mean) of cal numbers identified in the results from previous procedures.  The 
percent error was calculated for each resulting apparent activity data point.  The percent 
error data were then grouped across all 125I seeds and assay days by original seed 
calibration method (experimental or ADCL calibration, vendor calibration, vendor -12 hr, 
vendor +12 hr) and the mean, standard deviation and 95% CI were calculated for these 
groups.  The same statistical parameters were also considered for each individual seed 
over the five assay days. The total uncertainty (uncertainty budget) from all steps up to 
this point was calculated for each empirically determined 125I seed apparent activity.   
Ionization Chamber Survey Meter Calibration 
 The ionization chamber survey meter (451B, Fluke Biomedical, 6920 Seaway 
Blvd, Everett, WA 98203) does not have a dedicated mechanism to maintain a consistent 
geometry.  In order to ensure consistent geometry, a template was made with designated 
locations outlined for the survey meter and for the seed.  This setup is shown in Figure 4.  
Geometry configurations incorporating the same glass vial and HDR1000 single seed 
holder as in the activity calibrator procedures were used.  First, the seed was placed in the 
HDR1000 single seed holder, which was then placed on top of the small lead shipment 
container in order to elevate the seed so that it was approximately in line with the center 
of the ion chamber entrance window.  For the second geometry the seed was placed in the 
glass vial, which was then placed on top of a cube shaped piece of foam.    
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There were two main concerns with regard to geometry reproducibility.  The first 
potential source of error was distance between the seed and chamber window.  In order to 
assess the relevancy of this source of error, the seed (in vial/holder on top of elevation 
device) was moved in 2 mm increments from 30 cm to 29.2 cm, and five exposure rate 
measurements were recorded and averaged at each distance.  This process was repeated 
five times with the geometry being disassembled and reassembled after each set.  The 
second potential source of error considered was rotation of the seed.  Unlike the well 
chamber and activity calibrator, a survey meter does not envelope the seed.  Thus, an 
anisotropic radiation field will not be accurately measured with a survey meter.  For both 
geometries, the seed, vial and elevation device were rotated in 90º intervals with five 
exposure rate measurements recorded and averaged at each interval. This process was 
repeated five times with the geometry configuration being disassembled and reassembled 





















Figure 4.  Ionization chamber survey meter measurement geometry configurations for 
both the glass vial and HDR1000 single seed holder.  The 2 mm offset lines can be seen 
on the template for both geometry configurations. 
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Only Seed 1 and Seed 7 were used to determine the calibration factor in units of 
mR hr-1 mCi-1 (µSv hr-1 GBq-1) for the survey meter.  The calibration factor was 
calculated for each exposure rate data point in two sets, one utilizing the ADCL and 
experimental HDR1000 seed calibration and the other set using the vendor calibration.  
Calibration factor uncertainty was calculated with respect to three different sources of 
error.  The first two sources of error were the potential geometry errors discussed earlier 
(source to detector distance and variation when source is rotated), and the third source of 
error was variation in detector response and recording methods.  Ionization chamber 
survey meters do not typically settle on one stable exposure rate reading, and the 
procedures for recording data must account for this variation.  Thus the use of five 
exposure rate measurements recorded over short time intervals and averaged to create one 
data point.  Uncertainty due to errors in source-to-chamber distance was assessed by 
analyzing the calibration factors at varying distances for the same seed, on the same day.  
Variations in geometry assembly, chamber response and data recording methods were 
assessed by analyzing the calibration factors across the five sets of trials for the same 
seed, on the same day, at the same source-to-chamber distance.  Initially, the entire 
survey meter calibration process was to be repeated four more times on different days in 
order to investigate procedural reproducibility in terms of both time and seed radioactive 
decay.  Instead the process was repeated only once because variation in calibration 
factors was unacceptably high on both days.   
 From the set of calibration factors, minimum and maximum calibration factors 
were identified, and the mean calibration factor and calibration factors at ±1σ and ±2σ 
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from the mean were calculated for both Seed 1 and Seed 7.  The calibration factors were 
derived from four sets of data per geometry configuration, one set based on the 
experimental and ADCL calibrations with no variation in source-to-chamber distance, 
and one set based on the experimental and ADCL calibrations with variation in source-to-
chamber distance.  The other two sets were the same, except the vendor stated seed 
calibration was used.  Utilizing the eight sets of calibration factors, Seed 7 and Seed 8 
(the only seeds with activity high enough to be calibrated with a survey meter at this 
point in the experiments) were measured 20 times, and the average exposure rate was 
converted to apparent activity.  Each of the 20 Seed 7 and Seed 8 data points were the 
mean of five exposure rate measurements taken in the same manner as earlier to account 
for the inherent variation in ionization chamber survey meter readings.  The percent error 
was calculated for each apparent activity value.  Note that the HDR1000 single seed 
holder was positioned such that its support pillars were not between the seed and the 










ADCL 125I Seed Calibration 
 The apparent activity of Seed 1 was 0.1303 mCi (4.82 GBq or 0.1655 U) @ 
12/24/2014 10:49 AM, per ADCL calibration.  During the ADCL calibration, the seed 
was flipped end-over-end (180º) for half of the measurements, and there was a 0.1065% 
difference in the mean of the two sets of measurements.  There was no evidence of 125I 
seed anisotropy (with the length of the seed as the axis of rotation) when Seed 1 was 
tested qualitatively with a survey meter (the meter reading did not change with seed 
rotation) and assayed with the well chamber.  The results of the well chamber anisotropy 
test are shown in Table 1.  For the ionization chamber survey meter, there were other 
geometric problems with rotating the seed, which overshadowed any effects cause by 
inherent 125I seed anisotropy.  This resulted in instrument reading variations of greater 
than 60% with the HDR1000 single seed holder geometry configuration and greater than 
100% with the glass vial geometry configuration. 
 
Table 1.  Results from 125I seed anisotropy tests.  HDR1000 accumulated charge 
measurements with Seed 1 for 20 trials at 15 s intervals.  Note that the seed rotation was 




Max (pC) -10.80 -10.80 
Min (pC) -10.97 -10.98 
Max/Min % diff 1.6% 1.7% 
Mean (pC) -10.86 -10.89 
std dev (pC) 0.0394 0.0445 
CV 0.36% 0.41% 
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Well Chamber Calibration Coefficient 
 For each round of measurements (accumulated charge) made with the well 
chamber, several different combinations of charge collection times and number of trials 
were employed.  In general, varying between the averages of 5-trial, 10-trial and 20-trial 
measurement sets showed little statistical variation.  Assuming the 20-trial set to be the 
most accurate measurement of mean accumulated charge, two-tailed t-tests (mean of 20-
trial set used as theoretical mean) were performed on the 5-trial sets and 10-trial sets for 
each time interval (15s, 30s, 60s).  The results of the t-tests showed that the data in each 
set were not statistically different (95% CI) than the 20 trial set.  This held true for all 
seeds on every calibration round.  There was slightly more variation in the average 
charge accumulation within the 5 trial sets, as the percent difference between maximum 
and minimum values and the coefficient of variation were slightly higher.  Both of these 
statistical parameters increased with decreasing seed activity, ranging between <0.1% to 
3.1% and <0.1% to 1.31%, respectively.  
There was a consistent pattern of variation when different charge measurement 
times were employed.  This can be most easily seen by looking at the coefficient of 
variation of the well chamber calibration coefficient and the coefficient of variation of the 
calculated seed activity for different measurement times.  Increasing measurement time 
generally lowered the coefficient of variation by a factor of two for higher activity seeds 
and up to a factor of four for low activity seeds.  The coefficients of variation for each 
calibration coefficient and for each seed apparent activity result (For Seed 2 through Seed 
6) are shown in Table 2.  The only other parameter that had a noticeable effect on the 
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well chamber calibration coefficient and seed calibration uncertainty was the relative 
activity of the seed for any particular calibration.  Calibration with more recent, higher 
activity seeds yielded results with less variation.  This is also evident from the data in 
Table 2.  Rotation of the seed within the seed holder and flipping the seed end-over-end 
had no noticeable effect on outcomes.  Otherwise, the seed geometry within the well 
chamber was extremely stable.   
 Before the accuracy of the calibration results could be analyzed the 
accuracy and reproducibility of the empirical calibration coefficient of the well chamber 
used to calibrate each seed was verified.  Table 3 shows each chamber calibration 
coefficient derived from charge accumulation measurements of Seed 1 as well as the 
reference chamber calibration coefficient from the bi-annual chamber calibration 
performed May 13, 2014 at the MDACC ADCL.  The percent difference between the 
maximum and minimum chamber calibration coefficient was 1.49%, and the coefficient 
of variation was 1.14%.  Assuming a theoretical chamber calibration coefficient of 
0.1802 mCi pA-1 (6.67 GBq pA-1) (the chamber factor from the bi-annual ADCL 
calibration), a two-tailed t-test indicated that the empirical chamber calibration 
coefficients were not significantly different (95% CI) than the theoretical chamber 
calibration coefficient.  The first empirically derived chamber calibration coefficient of 
0.1784 mCi pA-1 (6.60 GBq pA-1) was chosen for use in calculations throughout this 




Table 2.  The coefficient of variation is shown for two sets of data.  The first set contains 
the coefficient of variation for the well chamber calibration coefficients based on 
measurements of Seed 1 on three different days.  The second set contains the coefficient 
of variation for the apparent activities of Seed 2 through Seed 7.  The calibration days 
ranged from 10/24/2014 to 11/9/2014 for the well chamber calibration coefficient and 
Seed 2 through Seed 6 apparent activity measurements.  The Seed 7 apparent activity 
measurement took place on 11/13/2014.  Note that Seed 7 had the highest apparent 
activity at the time of measurement.  Otherwise, apparent activity descends with 
increasing Seed number.  Also, note that the relationship between apparent activity and 
Seed number is not linear.  Seed 2 and Seed 3 (both received from the vendor in July 
2014) are very close in apparent activity, as are Seed 5 and Seed 6 (both received from 
the vendor in April 2014). 
  Coefficient of Variation (%) 
 Count Time (s) Day 1 Day 2 Day 3 
Calibration Coefficient CV    
 15 0.28 0.30 0.38 
 30 0.30 0.32 0.33 
 60 0.19 0.24 0.26 
          
Seed 2 activity CV    
 15 0.69 0.63 0.87 
 30 0.31 0.34 0.59 
 60 0.31 0.18 0.21 
Seed 3 activity CV    
 15 0.60 0.56 0.68 
 30 0.41 0.50 0.64 
 60 0.23 0.38 0.44 
Seed 4 activity CV    
 15 1.11 1.23 1.61 
 30 0.79 0.71 0.74 
 60 0.58 0.50 0.71 
Seed 5 activity CV    
 15 2.49 1.92 2.07 
 30 1.22 1.40 1.78 
 60 0.67 0.69 0.89 
Seed 6 activity CV    
 15 2.37 1.96 3.03 
 30 1.25 1.70 1.93 
 60 1.10 0.83 1.14 
Seed 7 activity CV    
 15 0.26     
 30 0.19     




Table 3. The HDR1000 well chamber calibration coefficient was measured on six 
different days.  On the first day, the calibration coefficient was determined by the 
MDACC ADCL.  The other five calibration coefficients were obtained by assaying Seed 
1.  Seed 1 was measured 20 times for 60 s per trial, and the results were averaged for use 








5/13/2014 ADCL Cal 0.1802±0.0036 
10/24/2014 0.130 0.1784±0.0006 
10/30/2014 0.121 0.1791±0.0007 
11/6/2014 0.112 0.1797±0.0011 
11/13/2014 0.103 0.1805±0.0007 














HDR1000 Well Chamber 125I Seed Calibration 
In a comparison of empirical seed calibration and vendor stated seed calibration, the 
smallest variation was found with Seed 2 and the largest variation with Seed 6.  The Seed 
2 activity calibration variation between empirical and vendor ranged from 0.02% to 
+0.34% difference (calibrated three times), and for Seed 6, the percent difference varied 
from -1.86% to -2.71%.  The empirical-vendor percent difference for all other seeds fell 
between these values.  Seed 1 was calibrated only one time by the ADCL with percent 
difference -0.84% compared to vendor calibration, while all other seeds were calibrated 
three times (Seed 7 was only calibrated two times) in the HDR1000 well camber, thus a 
range of percent difference values are given for Seed 2 through Seed 7.  All apparent 
activity data are shown in Table 4, including the vendor stated calibration (decay 
corrected).  Constancy tests were also performed each day with a 133Ba standard rod 
source (SS&DR No. CA0406S107S, Isotope Products Laboratory, 24937 Ave Tibbitts, 








Table 4. Apparent activity measurements (made in this work and by vendor) are shown 
for each seed along with the percent difference between the experimental measurements 







(mCi) % Difference 
Seed 1    
10/24/14 10:49 0.1303±0.0003 0.1314±0.0003 -0.84% 
Seed 2    
10/25/14 19:00 0.0750±0.0004 0.0750±0.0005 0.02% 
10/30/14 15:30 0.0711±0.0003 0.0709±0.0005 0.34% 
11/6/14 11:15 0.0655±0.0003 0.0654±0.0005 0.10% 
Seed 3    
10/25/14 18:00 0.0634±0.0003 0.0640±0.0009 -1.00% 
10/30/14 16:45 0.0595±0.0003 0.0604±0.0009 -1.57% 
11/6/14 12:35 0.0548±0.0004 0.0558±0.0009 -1.83% 
Seed 4    
10/25/14 19:45 0.0317±0.0002 0.0318±0.0006 -0.23% 
10/30/14 11:40 0.0294±0.0003 0.0301±0.0006 -2.32% 
11/6/14 13:30 0.0274±0.0002 0.0277±0.0006 -1.11% 
Seed 5    
10/25/14 19:45 0.0219±0.0002 0.0221±0.0006 -0.75% 
10/31/14 12:40 0.0201±0.0003 0.0206±0.0006 -2.67% 
11/6/14 14:15 0.0187±0.0002 0.0192±0.0006 -2.81% 
Seed 6    
10/25/14 21:30 0.0192±0.0002 0.0196±0.0011 -1.86% 
10/31/14 15:40 0.0178±0.0002 0.0183±0.0011 -2.71% 
11/6/14 15:50 0.0166±0.0003 0.0171±0.0011 -2.68% 
Seed 7    
11/13/14 13:30 0.1785±0.0008 0.1823±0.0008 -2.10% 
11/25/14 16:45 0.1588±0.0007 0.1582±0.0008 0.37% 
    
  mean % diff -1.31% 
  Stdev % diff 1.12% 
  95% CI lower -3.51% 








Table 5. Constancy tests were performed on the HDR1000 on each day that 125I seed 
assays were performed.  The average of six 15 s charge accumulations of a 133Ba standard 
rod source on each day are compared below.  All charge accumulation values (HDR1000 
measurements) are in units of pC.  The percent differences between the initial constancy 
measurements (10/24/2014) and subsequent measurements are given. 
 
Date 10/24/2014 10/25/2014 10/30/2014 10/31/2014 11/6/2014 11/13/2014 11/25/2014 
1 -4.08 -4.16 -4.05 -4.16 -4.26 -4.13 -4.02 
2 -4.13 -4.12 -4.02 -4.12 -4.18 -4.05 -4.05 
3 -4.06 -4.07 -4.07 -4.07 -4.17 -4.14 -4.03 
4 -4.13 -4.05 -4.01 -4.05 -4.17 -4.05 -4.00 
5 -4.04 -4.05 -4.08 -4.05 -4.06 -4.11 -3.99 
6 -4.06 -4.06 -3.99 -4.06 -3.99 -4.05 -3.98 
Mean -4.08 -4.09 -4.04 -4.09 -4.14 -4.09 -4.01 
% 













Activity Calibrator Calibration 
 It was found that exchanging two visibly identical glass vials, two visibly 
identical sample holders and HDR1000 single seed holders had little to no effect on 125I 
seed assay results.  In most cases the same cal numbers yielded the same apparent activity 
results.  When there was a discrepancy, the cal number only needed to be shifted a step or 
two (<1% change) in order to get the matching apparent activity, and there was no 
consistent pattern to this shift.   
The results of the tests for assay errors due to inconsistent recreation of the 
geometry configuration are shown in Table 6.  When the glass vial geometry 
configuration was carefully reproduced, the cal numbers ranged from 206 to 210, and 
when used to assay Seed 1 (0.1030 mCi (3.81 GBq) at the time of assay for this test), the 
maximum and minimum results were 0.1037 mCi (3.84 GBq) (0.62 % error) and 0.1023 
mCi (3.79 GBq) (-0.66 % error), respectively.  (Note that lowering the cal number setting 
increases the displayed apparent activity value).  The percent difference between these 
minimum and maximum apparent activity values was 1.28 %.  When the glass vial 
geometry configuration was intentionally varied, the cal numbers ranged from 190 to 
208, which yielded Seed 1 apparent activity values of 0.1097 mCi  (4.06 GBq) (6.54 % 
error) and 0.1023 mCi (3.79 GBq) (-0.66 % error). The percent difference between these 
minimum and maximum apparent activity values was 7.00 %.   For the HDR1000 single 
seed holder geometry configuration, careful reproduction of the geometry resulted in cal 
numbers ranging from 367 to 370.  This corresponded to 125I apparent activity values of 
0.1033 mCi (3.82 GBq) (0.29 % error) and 0.1026 mCi (3.80 GBq) (-0.35 % error), and 
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the percent difference between the two values was 0.64%.  Intentionally varying the 
HDR1000 geometry configuration resulted in minimum and maximum cal numbers equal 
to 362 and 368. The apparent activity displayed with these cal number settings was 
0.1046 mCi (3.87 GBq) (1.55 % error) and 0.1026 mCi (3.80 GBq) (0.33 % error), and 
























Table 6. The results of the geometry reproducibility tests for the activity calibrator are 
given below.  Both the percent error in the apparent activity values and the percent 
difference between the maximum and minimum apparent activity values were reasonably 
small except for the case of inconsistently reproduced geometry with the glass vial.   It is 
possible for the glass vial and the location of the seed to vary greatly inside the well of 
the activity calibrator.  The HDR1000 holder provided a tight fit within the dipper, and 
thus the well of the activity calibrator, which led to less variation in seed location.  All 
activity values are in units of mCi. 
 Glass Vial       
HDR1000 
Seed 
Holder     
             
  
Consistent 
Geometry       
Consistent 
















Min 206 0.10364  0.1030 0.62%  Min 367 0.1033  0.1030 0.29% 
Max 210 0.10232  0.1030 -0.66%  Max 370 0.10264  0.1030 -.035% 
             
% difference between max and min 1.28%   % difference between max and min 0.64%  
             
             
  
Inconsistent 
Geometry       
Inconsistent 
















Min 190 0.10974  0.1030 6.54%  Min 362 0.1046  0.1030 1.55% 
Max 208 0.10232  0.1030 -0.66%  Max 368 0.10266  0.1030 -.033% 
             








In determining the appropriate cal number for 125I seeds with the glass vial 
geometry configuration, the mean cal number for each seed’s experimental (or ADCL) 
calibration, vendor calibration, vendor -12 hr and vendor +12 hr apparent activity were 
207, 206, 207 and 204, respectively.  The cal numbers ranged, over all, from 196 to 225, 
or a 13.8 % difference between maximum and minimum, but the percent difference 
between the maximum and minimum cal number for the experimental (or ADCL) 
calibration 125I seed apparent activity was smaller at 6.27 %.  Variation in cal number for 
any one seed was generally much smaller.  For the experimental (or ADCL) calibration 
125I seed apparent activity, the percent difference between maximum and minimum cal 
number for an individual seed (over five measurement days) ranged from 0.48 % (Seed 
5) to 3.81 % (Seed 3).  There was no obvious correlation between 125I seed apparent 
activity and variation in cal number.  The full experimental cal number results (minimum, 
maximum, mean, standard deviation, coefficient of variation, ±1σ and ±2σ from the 
mean) for both geometry configurations are shown in Tables 7a and 7b.  For the 
HDR1000 single seed holder geometry configuration, the mean cal numbers were 369, 
368, 369 and 364 (experimental calibration, vendor calibration, vendor -12 hr and vendor 
+12 hr, respectively) with an overall range of 353 to 393 (10.7 % difference).  The 
percent difference between the maximum and minimum cal number for the experimental 
(or ADCL) calibration 125I seed apparent activity was 4.59 %, and the percent difference 
between maximum and minimum cal number for any one individual seed (over five 
measurement days) ranged from 1.62 % (Seed 1) to 3.78 % (Seed 7).  Again there was no 
correlation between seed activity and cal number variation.   
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Table 7a.  Variation in cal numbers obtained from assaying each 125I seed and adjusting 
the cal number setting until the correct apparent activity is displayed, for the glass vial 
geometry configuration.  The correct apparent activity was determined via experimental 
(or ADCL) seed calibration as described earlier, vendor stated activity (from calibration 
certificate) and vendor stated activity under the assumption that the date could be off by 
±12 hr if the exact time of day (hour and minute) is ignored.  Note that the mean cal 
numbers and ±1σ and ±2σ from the mean cal numbers need to be rounded before actual 
use. 
 
My Cal Vendor Cal -12 hr +12 hr 
Min 201 199 199 196 
Max 214 223 225 221 
% Difference 6.27% 11.37% 12.26% 11.99% 
mean 206.8 205.6 207.1 203.7 
stdev 3.1 7.4 7.7 7.5 
CV 1.49% 3.61% 3.74% 3.70% 
-σ 203.8 198. 2 199.3 196.1 
-2σ 200.7 190.8 191.6 188.6 
+σ 209.9 213.1 214.8 211.2 
+2σ 213.0 220.5 222.6 218.8 
 
 
Table 7b.  Same as Table 7a, except the HDR1000 single seed holder geometry was 
utilized. 
 
My Cal Vendor Cal -12 hr +12 hr 
Min 362 357 357 353 
Max 379 390 393 387 
% Difference 4.59% 8.84% 9.60% 9.19% 
mean 369.3 367.6 368.5 364.2 
stdev 4.6 10. 2 10.0 9.5 
CV 1.26% 2.77% 2.71% 2.62% 
-σ 364.7 357.4 358.6 354.6 
-2σ 360.1 347. 2 348.6 345.1 
+σ 374.0 377.7 378.5 373.7 






In order to assess the ability of an activity calibrator to accurately assay seeds, 28 
cal numbers (some happened to be duplicates) were chosen based on the analysis above.  
The 125I apparent activity values resulting from seed assays at the mean cal number for 
each seed calibration group (experimental calibration, vendor calibration, vendor -12 hr, 
vendor +12 hr) are shown in Table 8a and Table 8b, and the percent error (activity 
calibrator assay compared to “correct” HDR1000 calibration) for each data point is 
shown in Table 9a and Table 9b.  The mean percent error, standard deviation of the 
percent error data set and the mean percent error 95 % CI, across all seeds (Seed 1 
through Seed 5, Seed 7, Seed 8) are also shown in Table 9a and Table 9b. The mean 
percent error, standard deviation of the percent error data set and the mean percent error 
95 % CI, across the five assays of each individual seed are shown in Table 10.    The total 
uncertainty budget for each 125I apparent activity value obtained from seed assays using 














Table 8a. Apparent activity data obtained with the glass vial geometry configuration in 
the activity calibrator, utilizing the mean cal number settings (207, 206, 207, 204) based 
on four different initial 125I seed calibrations.  The theoretical activity is the seed activity 
calibrated in the HDR1000 (or ADCL for Seed 1) and decayed to the correct date.  The 









Vendor                      
-12hr 





between my cal 
and vendor cal 
1 DC 1 68.1 68.3 68.1 68.9 67.7 -0.29% 
1 DC 2 39.1 39.3 39.1 39.6 39.7 -0.51% 
1 DC 3 32.2 32.3 32.2 32.6 32.1 -0.31% 
1 DC 4 15.6 15.8 15.6 15.9 15.9 -1.27% 
1 DC 7 118.0 118.6 118.0 119.3 118.1 -0.51% 
1DC 8 200 201 200 202 200.7 -0.50% 
2 DC 1 65.0 65.3 65.0 65.7 64.6 -0.46% 
2 DC 2 37.4 37.5 37.4 37.7 37.9 -0.27% 
2 DC 3 32.2 32.4 32.2 32.6 31.7 -0.62% 
2 DC 4 15.6 15.6 15.6 15.7 15.6 0.00% 
2 DC 7 110.6 111.5 110.6 112.0 112.9 -0.81% 
2 DC 8 198 198 198 200 198.2 0.00% 
3 DC 1 60.3 60.5 60.3 61.1 60.3 -0.33% 
3 DC 2 34.9 35.0 34.9 35.2 35.4 -0.29% 
3 DC 3 30.1 30.3 30.1 30.4 29.6 -0.66% 
3 DC 4 14.6 14.6 14.6 14.7 14.6 0.00% 
3 DC 7 103.5 103.9 103.5 104.6 105.4 -0.39% 
3 DC 8 184 184 184 186 185.0 0.00% 
4 DC 1 60.0 60.1 60.0 60.4 59.5 -0.17% 
4 DC 2 34.1 34.2 34.1 34.4 34.9 -0.29% 
4 DC 3 29.8 29.9 29.8 30.1 29.2 -0.34% 
4 DC 4 14.5 14.5 14.5 14.6 14.4 0.00% 
4 DC 7 103.2 103.5 103.2 104.2 104.0 -0.29% 
4 DC 8 181 182 181 183 182.5 -0.55% 
5 DC 1 59.1 59.2 59.1 59.6 58.9 -0.17% 
5 DC 2 33.9 34.0 33.9 34.3 34.5 -0.29% 
5 DC 3 29.2 29.3 29.2 29.5 28.9 -0.34% 
5 DC 4 14.2 14.3 14.2 14.4 14.2 -0.70% 
5 DC 7 101.2 101.7 101.2 102.2 102.9 -0.49% 




Table 8b. Apparent activity data obtained with the HDR1000 single seed holder geometry 
configuration in the activity calibrator, utilizing the mean cal number settings (369, 368, 
369, 364) based on four different initial 125I seed calibrations.  The theoretical activity is 
the seed activity calibrated in the HDR1000 (or ADCL for Seed 1) and decayed to the 
correct date.  The day and Seed # column refers to the assay day (1-5) and the Seed # (1-





Seed # My Cal 
Vendor 
Cal 
Vendor                  
-12hr 





between my cal 
and vendor cal 
1 DC 1 67.6 67.7 67.6 68.2 67.7 -0.15% 
1 DC 2 39.5 39.7 39.5 39.9 39.7 -0.51% 
1 DC 3 32.1 32.1 32.1 32.3 32.1 0.00% 
1 DC 4 15.8 15.8 15.8 15.9 15.9 0.00% 
1 DC 7 117.2 117.8 117.2 118.5 118.1 -0.51% 
1DC 8 194 194 194 195 200.7 0.00% 
2 DC 1 64.6 64.9 64.6 65.2 64.6 -0.46% 
2 DC 2 37.3 37.5 37.3 37.7 37.9 -0.53% 
2 DC 3 31.6 31.7 31.6 32.0 31.7 -0.32% 
2 DC 4 15.8 15.8 15.8 15.9 15.6 0.00% 
2 DC 7 112.5 112.8 112.5 113.5 112.9 -0.27% 
2 DC 8 194 194 194 195 198.2 0.00% 
3 DC 1 60.2 60.4 60.2 60.8 60.3 -0.33% 
3 DC 2 34.9 35.0 34.9 35.3 35.3 -0.29% 
3 DC 3 29.7 29.8 29.7 29.9 29.6 -0.34% 
3 DC 4 14.7 14.7 14.7 14.8 14.6 0.00% 
3 DC 7 104.4 104.7 104.4 105.4 105.4 -0.29% 
3 DC 8 178 179 178 180 185.0 -0.56% 
4 DC 1 59.2 59.4 59.2 59.7 59.5 -0.34% 
4 DC 2 34.6 34.8 34.6 34.9 34.9 -0.58% 
4 DC 3 29.4 29.6 29.4 29.8 29.2 -0.68% 
4 DC 4 14.5 14.5 14.5 14.5 14.4 0.00% 
4 DC 7 103.1 103.2 103.1 104.0 104.0 -0.10% 
4 DC 8 177 177 177 179 182.5 0.00% 
5 DC 1 58.8 58.9 58.8 59.3 58.9 -0.17% 
5 DC 2 34.2 34.3 34.2 34.5 34.5 -0.29% 
5 DC 3 28.8 29.0 28.8 29.1 28.9 -0.69% 
5 DC 4 14.3 14.3 14.3 14.4 14.2 0.00% 
5 DC 7 103.2 103.4 103.2 104.2 102.9 -0.19% 
5 DC 8 175 175 175 177 180.7 0.00% 
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Table 9a. Percent error in apparent activity data obtained with the glass vial geometry 
configuration in the activity calibrator, utilizing the mean cal number settings (207, 206, 
207, 204) based on four different initial 125I seed calibrations.  The day and Seed # 
column refers to the assay day (1-5) and the Seed # (1-4, 7, 8). 
Day and Seed 
# My Cal 
Vendor 
Cal 
Vendor                  
-12hr 
Vendor                  
+12hr 
1 DC 1 0.64 0.93 0.64 1.82 
1 DC 2 -1.46 -0.96 -1.46 -0.20 
1 DC 3 0.33 0.65 0.33 1.58 
1 DC 4 -1.58 -0.32 -1.58 0.31 
1 DC 7 -0.07 0.43 -0.07 1.03 
1DC 8 -0.36 0.14 -0.36 0.64 
2 DC 1 0.55 1.01 0.55 1.63 
2 DC 2 -1.30 -1.04 -1.30 -0.51 
2 DC 3 1.66 2.29 1.66 2.92 
2 DC 4 -0.23 -0.23 -0.23 0.41 
2 DC 7 -2.04 -1.24 -2.04 -0.80 
2 DC 8 -0.12 -0.12 -0.12 0.89 
3 DC 1 -0.03 0.30 -0.03 1.29 
3 DC 2 -1.35 -1.07 -1.35 -0.51 
3 DC 3 1.82 2.50 1.82 2.84 
3 DC 4 0.06 0.06 0.06 0.74 
3 DC 7 -1.78 -1.40 -1.78 -0.74 
3 DC 8 -0.56 -0.56 -0.56 0.52 
4 DC 1 0.80 0.97 0.80 1.48 
4 DC 2 -2.31 -2.02 -2.31 -1.45 
4 DC 3 2.15 2.49 2.15 3.18 
4 DC 4 0.69 0.69 0.69 1.38 
4 DC 7 -0.72 -0.43 -0.72 0.24 
4 DC 8 -0.83 -0.29 -0.83 0.26 
5 DC 1 0.27 0.44 0.27 1.12 
5 DC 2 -1.77 -1.48 -1.77 -0.61 
5 DC 3 1.20 1.55 1.20 2.24 
5 DC 4 -0.35 0.35 -0.35 1.05 
5 DC 7 -1.68 -1.20 -1.68 -0.71 
5 DC 8 -0.41 -0.41 -0.41 0.14 
mean -0.29 0.07 -0.29 0.74 
stdev 1.18 1.17 1.18 1.18 
95% CI lower -2.61 -2.22 -2.61 -1.56 
95% CI upper 2.02 2.36 2.02 3.04 
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Table 9b. Percent error in apparent activity data obtained with the HDR1000 single seed 
holder geometry configuration in the activity calibrator, utilizing the mean cal number 
settings (369, 368, 369, 364) based on four different initial 125I seed calibrations.  The day 
and Seed # column refers to the assay day (1-5) and the Seed # (1-4, 7, 8). 






Vendor                  
-12hr 
Vendor                  
+12hr 
1 DC 1 -0.10 0.05 -0.10 0.79 
1 DC 2 -0.46 0.05 -0.46 0.55 
1 DC 3 0.02 0.02 0.02 0.65 
1 DC 4 -0.32 -0.32 -0.32 0.31 
1 DC 7 -0.75 -0.24 -0.75 0.35 
1DC 8 -3.35 -3.35 -3.35 -2.85 
2 DC 1 -0.07 0.39 -0.07 0.86 
2 DC 2 -1.57 -1.04 -1.57 -0.51 
2 DC 3 -0.23 0.08 -0.23 1.03 
2 DC 4 1.05 1.05 1.05 1.69 
2 DC 7 -0.35 -0.09 -0.35 0.53 
2 DC 8 -2.14 -2.14 -2.14 -1.63 
3 DC 1 -0.20 0.13 -0.20 0.79 
3 DC 2 -1.35 -1.07 -1.35 -0.22 
3 DC 3 0.47 0.81 0.47 1.15 
3 DC 4 0.74 0.74 0.74 1.43 
3 DC 7 -0.93 -0.64 -0.93 0.02 
3 DC 8 -3.80 -3.26 -3.80 -2.72 
4 DC 1 -0.54 -0.20 -0.54 0.30 
4 DC 2 -0.87 -0.30 -0.87 -0.01 
4 DC 3 0.78 1.46 0.78 2.15 
4 DC 4 0.69 0.69 0.69 0.69 
4 DC 7 -0.82 -0.72 -0.82 0.05 
4 DC 8 -3.03 -3.03 -3.03 -1.93 
5 DC 1 -0.23 -0.07 -0.23 0.61 
5 DC 2 -0.90 -0.61 -0.90 -0.03 
5 DC 3 -0.18 0.51 -0.18 0.85 
5 DC 4 0.35 0.35 0.35 1.05 
5 DC 7 0.26 0.46 0.26 1.23 
5 DC 8 -3.18 -3.18 -3.18 -2.07 
mean -0.70 -0.45 -0.70 0.17 
stdev 1.27 1.30 1.27 1.25 
95% CI lower -3.19 -3.00 -3.19 -2.27 
95% CI upper 1.79 2.10 1.79 2.61 
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Table 10. Each seed was assayed on five different days per cal number.  For the mean cal 
number, the mean percent error in apparent activity (activity calibrator assay compared to 
“correct” HDR1000 calibration), standard deviation in the percent error and percent error 
at the 95 % CI, across the five assays of each individual seed are shown below. 
 
Glass vial 








1 0.45 0.33 -0.20 1.09 
2 -1.64 0.41 -2.45 -0.83 
3 1.43 0.70 0.06 2.81 
4 -0.28 0.83 -1.91 1.34 
7 -1.26 0.83 -2.88 0.37 
8 -0.46 0.26 -0.97 0.06 
     
Seed 
Holder 






1 -0.23 0.19 -0.60 0.14 
2 -1.03 0.44 -1.89 -0.17 
3 0.17 0.44 -0.69 1.03 
4 0.50 0.52 -0.52 1.53 
7 -0.52 0.49 -1.47 0.43 









Table 11a.  Total uncertainty in final apparent activity values with the glass vial geometry 
configuration and mean calibration number.  The uncertainty values are given in both 































1 DC 1 68.1 1.0 1.5 68.3 2.5 3.6 68.1 2.6 3.8 68.9 2.6 3.7 
1 DC 2 39.1 0.7 1.7 39.3 1.4 3.7 39.1 1.5 3.8 39.6 1.5 3.8 
1 DC 3 32.2 0.5 1.7 32.3 1.2 3.7 32.2 1.2 3.8 32.6 1.2 3.8 
1 DC 4 15.6 0.3 2.1 15.8 0.6 3.9 15.6 0.6 4.0 15.9 0.6 4.0 
1 DC 7 118.0 1.8 1.6 118.6 4.3 3.6 118.0 4.4 3.8 119.3 4.5 3.7 
1DC 8 200 3.1 1.5 201 7.3 3.6 200 7.5 3.8 202 7.5 3.7 
2 DC 1 65.0 1.0 1.5 65.3 2.4 3.6 65.0 2.4 3.8 65.7 2.4 3.7 
2 DC 2 37.4 0.6 1.7 37.5 1.4 3.7 37.4 1.4 3.8 37.7 1.4 3.8 
2 DC 3 32.2 0.5 1.7 32.4 1.2 3.7 32.2 1.2 3.8 32.6 1.2 3.8 
2 DC 4 15.6 0.3 2.1 15.6 0.6 3.9 15.6 0.6 4.0 15.7 0.6 4.0 
2 DC 7 110.6 1.7 1.6 111.5 4.1 3.6 110.6 4.2 3.8 112.0 4.2 3.7 
2 DC 8 198 3.1 1.5 198 7.2 3.6 198 7.4 3.8 200 7.4 3.7 
3 DC 1 60.3 0.9 1.5 60.5 2.2 3.6 60.3 2.3 3.8 61.1 2.3 3.7 
3 DC 2 34.9 0.6 1.7 35.0 1.3 3.7 34.9 1.3 3.8 35.2 1.3 3.8 
3 DC 3 30.1 0.5 1.7 30.3 1.1 3.7 30.1 1.2 3.8 30.4 1.2 3.8 
3 DC 4 14.6 0.3 2.1 14.6 0.6 3.9 14.6 0.6 4.0 14.7 0.6 4.0 
3 DC 7 103.5 1.6 1.6 103.9 3.8 3.6 103.5 3.9 3.8 104.6 3.9 3.7 
3 DC 8 184 2.8 1.5 184 6.7 3.6 184 6.9 3.8 186 6.9 3.7 
4 DC 1 60.0 0.9 1.5 60.1 2.2 3.6 60.0 2.3 3.8 60.4 2.2 3.7 
4 DC 2 34.1 0.6 1.7 34.2 1.3 3.7 34.1 1.3 3.8 34.4 1.3 3.8 
4 DC 3 29.8 0.5 1.7 29.9 1.1 3.7 29.8 1.1 3.8 30.1 1.1 3.8 
4 DC 4 14.5 0.3 2.1 14.5 0.6 3.9 14.5 0.6 4.0 14.6 0.6 4.0 
4 DC 7 103.2 1.6 1.6 103.5 3.8 3.6 103.2 3.9 3.8 104.2 3.9 3.7 
4 DC 8 181 2.8 1.5 182 6.6 3.6 181 6.8 3.8 183 6.8 3.7 
5 DC 1 59.1 0.9 1.5 59.2 2.2 3.6 59.1 2.2 3.8 59.6 2.2 3.7 
5 DC 2 33.9 0.6 1.7 34.0 1.3 3.7 33.9 1.3 3.8 34.3 1.3 3.8 
5 DC 3 29.2 0.5 1.7 29.3 1.1 3.7 29.2 1.1 3.8 29.5 1.1 3.8 
5 DC 4 14.2 0.3 2.1 14.3 0.6 3.9 14.2 0.6 4.0 14.4 0.6 4.0 
5 DC 7 101.2 1.6 1.6 101.7 3.7 3.6 101.2 3.8 3.8 102.2 3.8 3.7 








Table 11b.  Total uncertainty in final apparent activity values with the HDR1000 single 
seed holder geometry configuration and mean calibration number.  The uncertainty 































1 DC 1 67.6 0.9 1.3 67.7 1.9 2.8 67.6 1.8 2.7 68.2 1.8 2.6 
1 DC 2 39.5 0.6 1.5 39.7 1.1 2.9 39.5 1.1 2.8 39.9 1.1 2.7 
1 DC 3 32.1 0.5 1.5 32.1 0.9 2.9 32.1 0.9 2.8 32.3 0.9 2.7 
1 DC 4 15.8 0.3 1.8 15.8 0.5 3.1 15.8 0.5 3.1 15.9 0.5 3.0 
1 DC 7 117.2 1.6 1.3 117.8 3.3 2.8 117.2 3.2 2.8 118.5 3.2 2.7 
1DC 8 194 2.6 1.3 194 5.4 2.8 194 5.3 2.7 195 5.2 2.7 
2 DC 1 64.6 0.9 1.3 64.9 1.8 2.8 64.6 1.8 2.7 65.2 1.7 2.6 
2 DC 2 37.3 0.5 1.5 37.5 1.1 2.9 37.3 1.0 2.8 37.7 1.0 2.7 
2 DC 3 31.6 0.5 1.5 31.7 0.9 2.9 31.6 0.9 2.8 32.0 0.9 2.7 
2 DC 4 15.8 0.3 1.8 15.8 0.5 3.1 15.8 0.5 3.1 15.9 0.5 3.0 
2 DC 7 112.5 1.5 1.3 112.8 3.2 2.8 112.5 3.1 2.8 113.5 3.0 2.7 
2 DC 8 194 2.6 1.3 194 5.4 2.8 194 5.3 2.7 195 5.2 2.7 
3 DC 1 60.2 0.8 1.3 60.4 1.7 2.8 60.2 1.6 2.7 60.8 1.6 2.7 
3 DC 2 34.9 0.5 1.5 35.0 1.0 2.9 34.9 1.0 2.8 35.3 1.0 2.7 
3 DC 3 29.7 0.4 1.5 29.8 0.9 2.9 29.7 0.8 2.8 29.9 0.8 2.7 
3 DC 4 14.7 0.3 1.9 14.7 0.5 3.1 14.7 0.5 3.1 14.8 0.4 3.0 
3 DC 7 104.4 1.4 1.4 104.7 2.9 2.8 104.4 2.9 2.8 105.4 2.8 2.7 
3 DC 8 178 2.4 1.3 179 5.0 2.8 178 4.9 2.7 180 4.8 2.7 
4 DC 1 59.2 0.8 1.3 59.4 1.7 2.8 59.2 1.6 2.7 59.7 1.6 2.7 
4 DC 2 34.6 0.5 1.5 34.8 1.0 2.9 34.6 1.0 2.8 34.9 1.0 2.7 
4 DC 3 29.4 0.4 1.5 29.6 0.9 2.9 29.4 0.8 2.8 29.8 0.8 2.7 
4 DC 4 14.5 0.3 1.9 14.5 0.5 3.2 14.5 0.5 3.1 14.5 0.4 3.0 
4 DC 7 103.1 1.4 1.4 103.2 2.9 2.8 103.1 2.8 2.8 104.0 2.8 2.7 
4 DC 8 177 2.3 1.3 177 5.0 2.8 177 4.9 2.7 179 4.7 2.7 
5 DC 1 58.8 0.8 1.3 58.9 1.6 2.8 58.8 1.6 2.7 59.3 1.6 2.7 
5 DC 2 34.2 0.5 1.5 34.3 1.0 2.9 34.2 1.0 2.8 34.5 0.9 2.7 
5 DC 3 28.8 0.4 1.5 29.0 0.8 2.9 28.8 0.8 2.8 29.1 0.8 2.7 
5 DC 4 14.3 0.3 1.9 14.3 0.5 3.2 14.3 0.4 3.1 14.4 0.4 3.0 
5 DC 7 103.2 1.4 1.4 103.4 2.9 2.8 103.2 2.8 2.8 104.2 2.8 2.7 





Ionization Chamber Survey Meter Calibration and 125I Seed Calibration 
 The variation in survey meter calibration factor was unacceptably high for each of 
the seeds that were measured.  Only Seed 1 and Seed 7 were measured for purposes of 
calculating the calibration factor, as none of the other seeds had sufficient apparent 
activity.  Seed 1 was later replaced with Seed 8 during the seed assay portion of the 
experiment.  The calibration factor results from one day of Seed 7 results follow as an 
example.  The survey meter calibration factors derived utilizing the glass vial geometry 
and Seed 7 at 30 cm seed-to-chamber window distance ranged from 1.04 mR hr-1 mCi-1 
(0.244 µSv hr-1 GBq-1) to 1.42 mR hr-1 mCi-1 (0.334 µSv hr-1 GBq-1) based on HDR1000 
initial 125I seed calibration and 1.03 mR hr-1 mCi-1 (0.242 µSv hr-1 GBq-1) to 1.40 mR hr-1 
mCi-1 (0.329 µSv hr-1 GBq-1) based on vendor initial 125I seed calibration.  The percent 
difference between maximum and minimum calibration factors was 30.9 % and 30.5 %, 
respectively.  This included variation in geometry due to disassembly and reassembly.  
When the source was moved closer to the detector in 2 mm increments (30 cm to 29.2 
cm) without disassembly and reassembly, the percent difference in calibration factors for 
each set of five incremental movements ranged from 5.35 % to 12.57 %.  The percent 
difference due to rotation of the glass vial ranged from 82.6 % to 102.7 % per set of four 
90˚ rotations. 
 The survey meter calibration factors derived utilizing the HDR1000 seed holder 
geometry at 30 cm seed-to-chamber window distance ranged from 1.20 mR hr-1 mCi-1 
(0.282 µSv hr-1 GBq-1) to 1.38 mR hr-1 mCi-1 (0.324 µSv hr-1 GBq-1) and 1.19 mR hr-1 
mCi-1 (0.280 µSv hr-1 GBq-1) to 1.36 mR hr-1 mCi-1 (0.320 µSv hr-1 GBq-1).  The percent 
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difference between maximum and minimum calibration factors was 14.0 % and 13.3 %, 
respectively.  This included variation in geometry due to disassembly and reassembly.  
When the source was moved closer to the detector in 2 mm increments (30 cm to 29.2 
cm) without disassembly and reassembly, the percent difference in calibration factors for 
each set of five incremental movements ranged from 5.04 % to 14.17 %.  The percent 
difference due to rotation of the HDR1000 single seed holder ranged from 50.28 % to 
61.81 % per set of four 90˚ rotations.   
 The mean calibration factors, minimum and maximum calibration factors, and 
calibration factors at ±1σ and ±2σ from the mean calculated from all calibration factors 
for both Seed 1 and Seed 7 are given in Table 12a and Table 12b.  There are four sets of 
calibration factors per geometry configuration; one set based on the experimental and 
ADCL calibrations with no variation in source-to-chamber window distance; one set 
based on the experimental and ADCL calibrations with variation in source-to-chamber 
window distance; and the other two sets were the same, except the vendor stated 125I seed 
calibration was used.  Included in Tables 12a and 12b is the percent error of the final 
Seed 7 and Seed 8 apparent activity measurements.  These percent error values varied 
widely with a minimum and maximum of 2.26 % and 46.40 % for Seed 7 with the glass 
vial geometry configuration and 2.98 % and 31.48 % for the HDR1000 single seed holder 
configuration.  For Seed 8 the minimum and maximum percent error values were 5.21 % 
and 42.13 % with the glass vial geometry configuration and 1.16 % and 30.67 % for the 
HDR1000 single seed holder configuration.  The low percent error values did not 
necessary correlate with the mean calibration factor as would be expected.  When the 
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mean calibration factor was used to obtain an apparent activity value the percent error 
was as high as 29.69 % with the glass vial geometry configuration and 13.9 % with the 
























Table 12a. The survey meter calibration factors (mR hr-1 mCi-1) (mean calibration factor, 
±1σ and ±2σ from the mean calibration factors, minimum and maximum calibration 
factors) are listed along with the percent error in the apparent activity values derived from 
the measured exposure rate data (unit conversion with calibration factors).  These are for 
the glass vial geometry configuration.  When the correction factor is listed at ~30 cm, it 
was derived from the set of exposure rate data where the source-to-chamber window 
distance was varied in 2 mm increments. 
 CF (My Cal) 30cm Seed 7 % Error Seed 8 % Error 
Min 0.7855 6.79% 15.72% 
-2σ 0.7776 7.87% 16.90% 
-σ 0.9620 12.80% 5.51% 
Mean 1.1464 26.83% 20.71% 
+σ 1.3309 36.97% 31.70% 
+2σ 1.5153 44.64% 40.01% 
Max 1.4249 41.13% 36.21% 
 CF (My Cal) ~30cm   
Min 0.6982 20.14% 30.19% 
-2σ 0.7907 6.09% 14.96% 
-σ 0.9782 14.25% 7.08% 
Mean 1.1657 28.04% 22.02% 
+σ 1.3532 38.01% 32.83% 
+2σ 1.5407 45.56% 41.00% 
Max 1.5035 44.21% 39.54% 
 CF (Vendor Cal) 
30cm 
  
Min 0.8203 2.26% 10.81% 
-2σ 0.8107 3.47% 12.12% 
-σ 0.9917 15.41% 8.34% 
Mean 1.1727 28.47% 22.49% 
+σ 1.3536 38.03% 32.85% 
+2σ 1.5345 45.34% 40.76% 
Max 1.4195 40.91% 35.96% 
 CF (Vendor Cal) 
~30cm 
  
Min 0.7291 15.05% 24.67% 
-2σ 0.8152 2.90% 11.50% 
-σ 1.0041 16.46% 9.47% 
Mean 1.1930 29.69% 32.81% 
+σ 1.3819 39.30% 34.22% 
+2σ 1.5708 46.60% 42.13% 
Max 1.5209 44.85% 40.23% 
 74 
Table 12b. The survey meter calibration factors (mR hr-1 mCi-1) (mean calibration factor, 
±1σ and ±2σ from the mean calibration factors, minimum and maximum calibration 
factors) are listed along with the percent error in the apparent activity values derived from 
the measured exposure rate data (unit conversion with calibration factors).  These are for 
the HDR1000 single seed holder geometry configuration.  When the correction factor is 
listed at ~30 cm, it was derived from the set of exposure rate data where the source-to-
chamber window distance was varied. 
 CF (My Cal) 30cm Seed 7 % Error Seed 8 % Error 
Min 0.7855 13.63% 6.09% 
-2σ 0.7776 27.42% 18.97% 
-σ 0.9620 10.16% 2.86% 
Mean 1.1464 2.98% 9.41% 
+σ 1.3309 13.32% 19.06% 
+2σ 1.5153 21.66% 26.86% 
Max 1.4249 16.95% 22.46% 
 CF (My Cal) ~30cm   
Min 0.6982 31.48% 22.76% 
-2σ 0.7907 20.23% 12.26% 
-σ 0.9782 5.86% 1.16% 
Mean 1.1657 5.43% 11.71% 
+σ 1.3532 14.56% 20.23% 
+2σ 1.5407 22.08% 27.25% 
Max 1.5035 21.22% 26.44% 
 CF (Vendor Cal) 30cm   
Min 0.8203 15.42% 7.76% 
-2σ 0.8107 29.44% 20.86% 
-σ 0.9917 9.31% 2.06% 
Mean 1.1727 5.41% 11.68% 
+σ 1.3536 16.63% 22.16% 
+2σ 1.5345 25.47% 30.42% 
Max 1.4195 19.64% 24.97% 
 CF (Vendor Cal) 
~30cm 
  
Min 0.7291 25.92% 17.57% 
-2σ 0.8152 21.61% 13.55% 
-σ 1.0041 4.89% 2.06% 
Mean 1.1930 7.79% 13.90% 
+σ 1.3819 17.73% 23.19% 
+2σ 1.5708 25.74% 30.67% 
Max 1.5209 24.54% 29.55% 
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CONCLUSIONS AND DISCUSSION 
Conclusions 
1. The radionuclide activity calibrator can be used to calibrate 125I brachytherapy 
seeds for use in RSL procedures.  The results of this work have shown that the activity 
calibrator can be calibrated (by determining an accurate calibration number for a specific 
seed type and vendor) so that 125I seed assays are accurate (percent error <5% when 
compared to theoretical source strength), precise (small standard deviation), contain 
relatively small uncertainty (CV = ~3% or less) and are reproducible over time and for 
seeds of varying apparent activity.  For the glass vial geometry configuration, when the 
percent error in apparent activity values of all seeds are pooled and averaged (considering 
only activity calibrator assays with the mean cal number), the sample mean percent error 
was -0.29 %, and the true mean percent error was between -2.61 % and 2.02 % with 95 % 
confidence for experimental (HDR1000) calibration and -2.22 % and 2.36 % (95 % CI) 
for vendor calibration (See Table 9a).  For the average of individual seed (over five seed 
assay days) percent error in apparent activity values, the variation in mean value was less 
than when all seeds are pooled together (See Table 10).  For vendor calibration with a 
±12 hr offset (still based on mean cal number) the highest percent error for any single 
data point was 3.18% and the mean percent error was within ±1%.  For the HDR1000 
single seed holder geometry configuration, the sample mean percent error was -0.70 %, 
and the true mean percent error was between -3.19 % and 1.79 % with 95 % confidence 
for experimental (HDR1000) calibration and -3.00 % and 2.10 % (95 % CI) for vendor 
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calibration, which were both slightly wider than for the glass vial geometry configuration. 
All of these values fall well within the regulatory limit of 10 % as well as the 
recommended internal check limit of 5%.  For brachytherapy procedures, AAPM Report 
# 84 gives a dose rate uncertainty analysis, which assumes an uncertainty of at least 3% 
in source strength (Rivard et al. 2004).  The total uncertainty in apparent activity 
(considering only activity calibrator assays with the mean cal number) is comparable for 
both the glass vial and the HDR1000 single seed holder (See Table 11).  For almost every 
seed assay with the HDR1000 single seed holder, the total uncertainty is actually less 
than 3%.  
 
2. The initial HDR1000 calibration apparent activity for each seed is compared to 
vendor stated apparent activity in Table 4.  The final experimental calibration (with 
radionuclide activity calibrator) apparent activity values are given in Table 8.  
Interestingly, the final percent difference in experimental and vendor calibration data (see 
last column of Table 8) show considerably less variation than the initial percent 
difference in HDR1000 calibration and vendor calibration data (see last column of Table 
4).  Apparently, the measurement and averaging process used to obtain the mean cal 
number produced nearly identical cal numbers for each set of 125I seed initial calibration 
values (experimental calibration, vendor stated calibration, and vendor ±12 hr).  
 Paired t-tests were performed on the eight sets of apparent activity percent 
difference data (See Table 9).  For the glass vial geometry configuration, the four data 
sets were not statistically different from each other.  For the HDR1000 single seed holder 
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geometry configuration, the difference between the data sets was significant.  This was 
due to the percent error in Seed 8 apparent activity measurements, which were slightly 
over 3%.  Most of the data points for the other seeds were below 1%.  Removing this 
seed from the data resulted in data sets that were no longer statistically different.    When 
comparing data sets between the two geometry configurations, the difference was 
significant. 
 
3. The ionization chamber survey meter cannot be used to calibrate 125I 
brachytherapy seeds for use in RSL procedures with the methods investigated in this 
work.  Human error in exposure rate data collection and thus, calibration factor 
determination, was substantial.  Even if geometry reproducibility was perfect (which it 
certainly is not), the inherent instability in exposure rate readout produces unacceptable 
variation in data.  Even the mean calibration factors produced apparent activity values 
with percent error greater than 10 % (See Table 12).  When source rotation is factored in, 
the percent error values become considerably larger.  Source rotation is inevitable with 
the glass vial and can lead to calibration factor percent error values greater than 100 %.  
This is because inside the glass vial, the seed can rotate so that either the end or the 
horizontal (length or height) side of the seed (or anywhere in between) faces the detector.  
The radiation field is quite different in these two orientations.  In the case of the 
HDR1000 single seed holder, the seed rotates with the seed length (height) as its axis.  In 
this rotational field, the source is isotropic, yet still rotation caused calibration factor 
percent error values greater than 60 %.  This is due to the physical design of the 
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HDR1000 single seed holder.  There are three thin “pillars” that assure the structural 
integrity of the seed holder.  If one of these pillars is in between the seed and the detector 
window, the exposure rate at the detector window will drop off significantly. 
 
4. The percent error in the apparent activity measurements made with the activity 
calibrator decreased with increasing 125I seed activity.  This was quite noticeable when 
assaying all seeds (initial seed vendor calibrations spanning nine months).  This 
relationship was not evident on short time scales.  When observing individual seeds (5 
measurements over 1-2 months), the percent error data did not correlate strongly with 
seed activity.  
 
5. In practice, an institution performing RSL procedures should not need to duplicate 
every step of this thesis work before deploying a general-purpose radionuclide activity 
calibrator for RSL seed source strength verification.  A geometry configuration would 
need to be selected and tested for reproducibility if the configuration differs from the two 
configurations presented in this thesis.  While it may not be necessary or practical to 
assay six different seeds, a single seed would not be sufficient.  Multiple seeds (from the 
seed vendor) possessing NIST traceable calibration should be assayed in the radionuclide 
activity calibrator in order to determine the optimal calibration number (or correction 
factor if a factory calibration number is utilized).  Three is recommended as a minimum 
number of seeds, and the mean calibration number (or correction factor) from these 
assays should be used in future RSL seed assays.    Ideally, the 125I seed vendor should 
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provide proof of NIST traceability for the first three calibration seeds that it sends to an 
institution starting a RSL program.  Alternatively, three seeds (from any recent batch) 
could be sent to an ADCL to receive a NIST traceable calibration.   
Summary of Contributions 
I have demonstrated that a general-purpose radionuclide activity calibrator can be used 
for RSL seed calibration by following the steps put forth in this thesis.  While all 
experiments were performed with only IsoAid 125I seeds, it is expected that these 
procedures will work with seeds from other vendors, although the calibration number 
may be different.  This would obviate the need for a specialized brachytherapy seed 
calibration system within a clinic that only uses these seeds for RSL procedures.  I have 
also proven the feasibility of two reproducible seed assay geometry configurations.  The 
HDR1000 single seed holder can be purchased separately from the HDR1000 well 
chamber system, and it is a very good fit with the activity calibrator sample holder used 
in this work.  Geometry reproducibility tests show that it is not possible for the user to 
introduce significant error through careless reproduction of the HDR1000 single seed 
holder geometry configuration.  On the other hand, the user must be more careful when 
using the glass vial that the 125I calibration seed is shipped in as part of the activity 
calibrator seed assay geometry configuration.  Geometry reproducibility tests have shown 
that if the glass vial is placed in the center of the sample holder every time, then 
reproducibility is achieved, but unacceptable uncertainty can be introduced if the glass 
vial position varies within the sample holder. 
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I have provided evidence that the choice of initial 125I apparent activity (in-house 
HDR1000 versus vendor stated valued) for use in determining the optimal activity 
calibrator cal number is potentially less crucial than one might expect.  The differences 
between initial 125I apparent activity caused only slight variation in cal number, and in 
turn, small variation in the results of activity calibrator assays.  Thus, even though the 
half-life of 125I is short enough to justify using exact times (hour and minute), if only the 
exact day is used, apparent activity verification measurements made with a activity 
calibrator can still be sufficient for regulatory purposes. Furthermore, a two-tailed t-test 
shows that the eight sets of percent error in apparent activity data (four per geometry 
configuration) are not statistically different from each other.     
  
Finally, I have provided evidence that in-house 125I seed apparent activity measurements 
made with a HDR1000 well chamber are generally within 3 % of apparent activity values 
given by IsoAid on the vendor calibration certificate (See Table 4).  A larger number of 
125I seeds would need to be assayed in order to verify this. 
Future Research 
1. The calibration methodology put forth in the Conclusions section should be 
developed into a formally written procedure, tested and implemented by qualified 
medical physicists in institutions currently performing RSL procedures.  The written 
procedure should be as efficient as possible without compromising regulatory 
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compliance.  The methodology given in the Conclusions section recommends that the 
physicist utilize three NIST traceable seeds, contrary to the eight total seeds used in this 
thesis work.  Future research should aim to verify that three seeds are sufficient to 
determine the optimal cal number.  
 
2. The relationship between 125I seed activity and the percent error in the apparent 
activity measurements made with the activity calibrator should be further analyzed.  In 
subsequent experiments, the number of calibration seeds should be increased in order to 
substantiate the third conclusion made above, and the seeds should be measured more 
frequently and for a longer overall period of time to determine specific limits on how 
long after vendor seed calibration the 125I can be assayed in the activity calibrator while 
keeping the percent error in the measurement reasonable.  The second conclusion above 
should also be further investigated utilizing a greater number of seeds.  It would be very 
convenient for the user if the second conclusion were proven to be true in general.  It 
would also be useful to quantify the limits to the amount of variation in initial 125I seed 
apparent activity calibration that will still allow for consistent activity calibrator cal 
number selection and assays with acceptable percent error. 
 
3. Despite the disappointing data obtained with the ionization chamber survey meter, 
a more refined experiment might yield better results.  The glass vial geometry 
configuration should not be used, and the HDR1000 single seed holder geometry 
configuration should always be set up in such a way that the support pillars do not 
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obstruct the radiation field between the source and the detector.  Most importantly, the 
methodology for obtaining survey meter measurement results must be more accurate.  
This could be achieved by recording the data with the built-in software.  An 
adapter/computer interface cable (RS-232, Fluke Biomedical, 6920 Seaway Blvd, 
Everett, WA 98203) is used to connect the survey meter to a computer.  This software 
automatically records and stores (in a Microsoft Excel spreadsheet on the host computer) 
exposure rate measurements at predefined time intervals.  Averaging a large number of 
readings over consistent time intervals could result in improved accuracy and 
reproducibility. 
 
4. Other radiation detection instruments might be serviceable for 125I seed source 
strength verification.  Specifically, any instrument capable of low-energy gamma 
spectroscopy should be investigated.  NaI detectors, both benchtop and portable could 
theoretically be placed in a fixed geometry for gamma spectrum data acquisition and 
analysis.  A NaI thyroid bioassay system may already be in place if the institution 
performing RSL procedures has a nuclear medicine department.  Spectroscopy systems 
based on CdTe crystals have become more common and are excellent for low-energy 
gamma and x-ray spectroscopy, as well.  Success with any of these systems will be 
highly dependent on reproducibility of a fixed geometry.  These systems are also more 
time intensive (than radionuclide activity calibrator measurements) and require staff that 
is experience with gamma spectroscopy. 
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Appendix A   





Annual accuracy test for activity calibrator used in this thesis work.  The accuracy test 
was performed by Department of Imaging Physics staff. 
 
Dose Calibrator Annual Test: 
Accuracy        
          
Location  
ACB NM 
RIA Lab        
CAPINTEC Serial No. 157227        
Measurement Date 12/17/14        
          
Reference Isotope Information:         
          




Setting    
Co-57 BM06057E10260109 5620.0 9/23/10 271.7 d 112    
Ba-133 BM0633-004-09 258.0 8/29/05 10.5 yr 591    
Cs-137 BM0637-012-40 204.0 8/22/05 30 yr 220    
Sr90/Y90 12974B 32490.0 3/11/05 28.79 yr 056x10    
* source form-factor: Benchmark E-Vials, except for the Sr90/Y90 transfer standard     
          
Accuracy PASS Threshold [%] 5        
          
Reference Expected Measurements of Activity [uCi] Mean Std. Dev.  CV Accuracy   
Isotope Activity [uCi] #1 #2 #3 [uCi] [uCi] [%] [%]   
                  
Co-57 109 108 109 108 108.3 0.6 0.53 -0.5 PASS 
Ba-133 140 144 143 143 143.3 0.6 0.40 2.7 PASS 
Cs-137 164 168 168 167 167.7 0.6 0.34 1.9 PASS 
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